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Summary. 
 
Alkyl vitamin C derivatives (ASCn) are amphiphilic molecules having physicochemical 
properties that depend on the alkyl chain length. The derivatives with low molecular weight 
(n < 11) have enough aqueous solubility to produce self-assemblies at room temperature 
(≈25°C), while those with longer alkyl chains possess a critical micellar temperature 
(CMT) higher than 30°C. Above CMT aqueous ASCn derivatives suspensions turn into 
either micellar solutions or gel phases, depending on the length of the alkyl side chain. On 
cooling, liquid crystal structures, called coagels, are produced.  
The semisolid consistency of such coagels is an interesting property that makes ASCn 
coagel a promising pharmaceutical platform for drug delivery. Coagels could be able to 
solubilize insoluble and unstable drugs, protect them from any possible aggressive 
environment and enhance their permeation through skin. Furthermore the rheological 
properties of coagels would be adequate for topical administration. 
Aim of the study was the evaluation of L-ascorbic acid lipophilic derivatives as permeation 
enhancers for two non-steroidal antinflammatory drugs, ibuprofen (IBU) and diclofenac 
(DICH), through hairless rat skin and ocular structures of rabbit eye, respectively, by means 
of in vitro, ex vivo and in vivo studies. 
Among lipophilic derivatives the lauroyl-6-O-ascorbic acid or ascorbyl-laurate (ASC12) and 
the palmitoyl-6-O-ascorbic acid or ascorbyl palmitate (ASC16) were chosen and different 
vehicles for both IBU and DICH were prepared and compared with the commercially 
available formulations. The rheological characterization of each formulation was 
performed. Moreover, in order to better define the physicochemical properties of ASC12 
and ASC16, the effect of the co-solvent on their drug-loading capacity was evaluated using 
two insoluble model drugs, anthralin (ANTH) and griseofulvin (GRIS). Preliminary studies 
on the stability of ASC16 were conducted in the presence or absence of vitamin E (Vit E), 
used as antioxidant. 
Results showed that both ASC12 and ASC16 increased IBU transdermal permeation through 
hairless rat skin, producing a low depot in the skin of the same order of magnitude for both 
epidermis and dermis. Furthermore, a synergistic enhancement effect between ASCn and 
PEG400 was observed, more evident for ASC12PEG400/CIbu coagel. 
 II
In vivo studies on rabbit eyes demonstrated that even if coagels did not increase the 
retention time of DICH in the tear fluid with respect to the commercial formulation, they 
were capable to raise drug concentration in the aqueous humour of two and three folds for 
ASC16 and ASC12, respectively. 
The incorporation of both IBU and DICH in the system did not produce changes on the 
characteristic crystalline structure of coagel, as observed from rheological measurements.  
The solubility profiles showed that the solubility of the model-drugs (ANTH and GRIS) 
was higher when the amount of the co solvent increased and a synergistic effect of PEG 
400 and ASC16 coagel on the solubility of such drugs was observed. 
Finally, preliminary stability studies demonstrated that the presence of Vit E as antioxidant 
did not improve the stability of ASC16, which showed a quicker degradation at 60°C with 
respect to room temperature. 
In conclusion, ASCn coagels may be considered promising pharmaceutical systems for 
drugs utilizing  by  topical administration, even if further studies would be performed to 
increase their  stability. 
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1. Introduction 
 
1.1. The Skin  
 
 
The skin has the primary function to provide a barrier against environmental influences 
and to protect the body against the loss of endogenous substances. Furthermore, the skin 
is also a major contributor to thermoregulation and performs endocrine functions, e.g. 
Vitamin D synthesis or peripheral conversion of pro-hormones. Macroscopically, two 
distinct skin layers are present, an unvascularized outer layer (epidermis) and an inner 
vascularized layer. The vascularized layer consists of the dermis and the hypodermis 
and has the function to provide physiological support to the unvascularized epidermis. 
This layer comprises the viable epidermis and the outermost layer of the skin, the 
stratum corneum, which consists of dead keratin-filled cells. Figure 1 gives an overview 
about the dimensions and the stratified appearance of the skin. 
 
 
 
 
 
 
Figure 1  Structure of the human skin. 
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1.1.1. The Viable Epidermis and Epidermal Differentiation 
 
The viable epidermis is divisible into three distinct layers, namely, from inside to 
outside: stratum basale, stratum spinosum and the stratum granulosum. The cells of 
these layers undergo continuous differentiation to produce the outermost layer of the 
skin, the stratum corneum, that consists of layers of dead keratin filled cells. Due to this 
process, histological preparations of the epidermis are of stratified appearance. 
The stratum basale is a single layer of epidermal stem cells which are anchored to a 
basement membrane that separates the epidermal tissue from the underlying dermis. The 
basal cells are continually dividing, creating cells that undergo several changes while 
moving towards the skin surface in further course of differentiation. Above, these 
differentiating cells are forming the stratum spinosum. The cells are now of spiny 
appearance, due to abundance of desmosomes. 
In addition to the cell organelles seen in the basal layer, the stratum spinosum also 
reveals lipid enriched lamellar bodies (also called Odland bodies) and an increase in 
keratin filaments, indicating the dual character of the differentiation, protein and lipid 
synthesis (Menon, 2002). On their way to the skin surface, the cells begin to flatten and 
elongate, forming the stratum granulosum. Distinct keratohyalin granules that become 
larger in the upper granulocytes reflect an increase in keratin synthesis, accompanied by 
an increasing number of lamellar bodies. In course of the terminal differentiation of the 
uppermost granulocytes into a corneocyte, these lamellar bodies are secreted to the 
extracellular domains, forming the stratum corneum extracellular bilayers. This process 
is accompanied by the formation of the corneocyte`s cornified envelope, the dissolution 
of cell organelles and the condensation of the enriched keratin filaments. The nature of 
the signals that initiate the irreversible process of cornification isn’t still elucidated, but 
it is evidenced that an extracellular calcium gradient with higher Ca2+ concentrations in 
the upper regions of the viable epidermis triggers the transformation from a granulocyte 
to a corneocyte. The deceased cells are finally shed from the skin by desquamation. The 
complete renewing process takes about 3-4 weeks. The viable part of the epidermis also 
contains melanocytes that are responsible for skin pigmentation, antigen presenting 
Langerhans cells and Merkelcells (mechanoreceptors) (Stenn, 1983). 
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1.1.2. The Stratum Corneum 
 
The stratum corneum constitutes the outermost layer of the epidermis and represents the 
main barrier function, although it is the thinnest and smallest compartment of the skin. 
It is about 10 to 20 μm thick and consists of several layers of dead, keratin filled 
corneocytes that represent the final state of epidermal differentiation. These cells are 
embedded in a matrix of lipid lamellas that descend from the secreted content of the 
lamellar bodies, which gives the stratum corneum a brick and mortar organization 
(Menon, 2002). A rigid envelope that replaces the plasma membrane surrounds the 
corneocytes after terminal differentiation. This cornified envelope in turn is coated with 
long chain ceramides, some of them covalently attached through ester linkages to the 
outer surface of the envelope. A free interaction of their acid chains with unbound 
extracellular lipid lamellae assists establishing the lamellar organization in the 
extracellular lipids (Candi et al., 2005). Another specialty of the stratum corneum is the 
lipid composition, which differs significantly from those of the cells of the lower 
epidermal layers. The lipid composition of the stratum basale is comparable with that of 
cells of other tissues and constitutes mainly of phospholipids. In the stratum 
granulosum, a drastically decrease in the phospholipids occur for the benefit of 
sphingolipids and cholesterol. The extracellular lipid matrix of the stratum corneum 
finally is free of phospholipids and consists of ceramids, cholesterol and free fatty acids 
in roughly equimolar ratios (Menon, 2002). The ceramides are crucial for the lipid 
organization of the stratum corneum barrier, while the cholesterol is promoting the 
intermixing of different lipid species. Figure 2 points out these differences in lipid 
composition for the stratum basale, the stratum granulosum and the stratum corneum.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Lipid composition of different epidermal layers. (Schaefer and 
Redelmaier, 1996) 
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Water-holding properties of the stratum corneum are influenced by the rate of 
proteolysis, which generates a blend of amino acids termed as natural moisturing factors 
(Rawlings et al.,  1994). The general degree of hydration of the stratum corneum is 
between 10 to 30% bound water, depending on the location within the stratum corneum, 
body site and environmental conditions. Under occlusive conditions (defined as 
complete impairment of passive transepidermal water loss), however, the stratum 
corneum may bind a 2.75 fold amount of water compared to its dry weight (Nitsche et 
al.,  2006). 
 
 
1.1.3. The Dermis and the Hypodermis 
 
The dermis is connected by the basement membrane to the stratum basale. This junction 
is of folded appearance, supporting the exchange of nutrients and other physiological 
substances with the unvascularized epidermis. Main components of the dermis are 
collagen and elastin fibres that form a vast network of filamentous and amorphous 
connective tissue that prevents strength and flexibility to the skin (Schaefer and 
Redelmaier,  1996). Furthermore, the dermis accommodates cellular residents such as 
fibroblasts, endothelial cells, mast cells and, under conditions of inflammation, 
macrophages, lymphocytes and leucocytes. The tissue of the dermis has an extensive 
vascular network that is involved in nutrition, thermal regulation and immune 
responses. A variety of appendages, such as hair follicles or sweat and sebaceous glands 
are also derived from this tissue. Underneath the dermis is the hypodermis situated that 
contains, in contrast to the dermis, loose connective tissue and adiposities as the main 
cellular exponent which represent an energy source for the body. 
 
 
1.1.4  Dermatological Vehicles 
 
In clinical situations, a drug is rarely applied to the skin in form of a pure chemical but, 
instead, is normally incorporated in a carrier system, the vehicle (Surber and Smith, 
2005). Such preparations vary in their physicochemical nature from powders through 
semisolids to liquids. However, a uniform and comprehensive classification for 
dermatological vehicles is currently not yet available. A formulation may be classified 
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by its pharmaceutical nomenclature used in pharmacopoeias (e.g. cream, ointment, gel), 
by the principle of the structural matrix (e.g. emulsion, liposomal dispersion) or by 
macroscopic appearance (e.g. milk, foam, shake). Table 1 gives a simplified possible 
classification of dermatological vehicles. 
 
 
Table 1  Simple classification of dermatological vehicles 
 
                                                                      
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is obvious that this classification system is a raw simplification of the diversity of 
external formulations. It does not account for many of the newer external formulations 
(e.g. liposomes, microcapsules, microemulsions, ect.) (Surber and Smith, 2005). 
 
 
 
 
 
emulsion (o/w, w/o) 
often designated as 
milk, lotion, shake, ect. 
 
suspension 
often designated as 
paint, shake, ect. 
nonpolar solution,  
often designated as oil 
 
polar solution 
often designated as 
paint, lotion, ect 
emulsion (o/w/o) 
often designated as milk, 
lotion, shake, ect. 
 
suspension 
often designated as 
paint, shake, ect. 
Liquid     
Semisolid water-free polar or 
nonpolar ointment 
 
water containing polar 
or nonpolar gel 
emulsion (o/w, w/o) 
often designated as 
washable (o/w), 
nonwashable (w/o)or 
amphiphilic (o/w, w/o) 
cream 
 
suspension 
often designated as 
paste.
emulsion with powder 
(o/w,w/o) 
often designated as 
cream 
 
pastes 
Solid powder transdermal patch 
System Monophasic Diphasic    Tri-(multi-)phasic 
transdermal patch 
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1.1.5. Permeation Routes 
 
The permeation of drugs through the skin includes the diffusion through the intact 
epidermis and trough skin appendages, for example sweat glands and hair follicles. 
However, the appendages occupy only 0.1% of the human skin surface so that the 
contribution of these shunt pathways to transdermal permeation is usually considered to 
be small (Moser et al.,  2001).  
Theoretically, there are two pathways through this layer (Figure 3): a transcellular 
(across the corneocytes and the lipid matrix) and an intercellular way (via the 
intercellular lipid domains between the corneocytes). In both cases, however, the 
permeant has to pass the intercellular lipid matrix. 
Intercellular lipids are arranged in multiple layers, containing both, polar and nonpolar 
components. This suggests that hydrophilic and lipophilic penetrants diffuse through 
different domains in the lipid matrix. The transcellular pathway is generally the 
unfavoured route for a drug to permeate through the stratum corneum because of the 
high diffusional resistance of the cornified cells (Hadgraft, 1983). Only hydrophilic 
molecules such as water or short-chain alcohols seem to prefer the transcellular pathway 
(Barry,  1983). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 . Schematic representation of stratum corneum and its intercellular and 
transcellular pathways of drug permeation (Moghimi et al.,  1999). 
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1.1.6 Factors Affecting Drug Permeation Through the Skin 
 
Several biological and physicochemical parameters may influence drug permeation 
across the skin (Barry, 1983). The physicochemical factors that control the passive 
diffusion of a substance from a vehicle into and across the skin are determined by the 
molecular properties of the substance, the vehicle and the skin. Skin hydration is a 
crucial and possibly the most frequently investigated factor affecting drug permeation. 
Alterations the vehicle following application, commonly due to evaporation of volatile 
components, represent a further crucial parameter that may affect drug permeation. 
Furthermore, skin metabolism may have additional impact on transdermal delivery of 
drugs. As  skin undergoes many structural and functional changes with increasing age it 
would be useful to know whether such alterations affect the transdermal diffusion of 
drugs. Studies have shown that the effect of age is rather due to the smaller surface-to-
volume ratio in case of newborn infants compared with adults than to an effect of the 
lower barrier function of younger skin (Walters, 1986). In practice, there is often a 
combination of these factors that contribute to transdermal drug permeation. 
 
• Skin Hydration and Occlusion 
• Evaporation of Volatile Vehicle Compounds Following Application 
• Drug-Skin Interactions 
• Drug-Vehicle Interactions 
• Vehicle-Skin Interactions 
 
 
1.1.7. Strategies to increase drug penetration through the skin. 
 
Since many drugs do not permeate the skin well enough to be suitable for a transdermal 
formulation several technological approaches have been studied in the recent decades to 
enhance percutaneous drug penetration 
Methods for improving cutaneous delivery may consist either on the use of chemical 
penetration enhancers, novel vehicle systems (i.e. microemulsions, liposomal-based 
delivery systems), or physical enhancement strategies (iontophoresis, sonophoresis, and 
electroporation). non-toxic, non-allergenic, compatible with drugs and excipients and 
non-irritating when removed from the skin, barrier properties should return back rapidly 
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and fully and they should not have pharmacological activity. Many enhancers exhibit 
these attributes, e.g. azone and its analogues (Michniak et al., 1993), fatty acids (Aungst 
et al., 1990) alcohols (Takahash et al., 1991), pyrrolidones (Babu et al.,  2008), 
sulfoxides (Choi et al.,  1991), 6-O-ascorbic acid alkanoates (Palma et al.,  2006), urea 
and its analogues and terpenes (Williams and Barry, 1991).  
Referring to Fick’s first law three permeation enhancement strategies may be 
postulated: 
 
1) Increasing the diffusion coefficient. 
A reduction of the diffusional resistance of the skin can be obtained by disordering the 
stratum corneum lipids. Fatty acids are generally believed to increase diffusivity across 
the stratum corneum. Oleic acid, for example, has been shown to induce phase 
separation in the stratum corneum lipid domains, thereby reducing barrier function. 
Azone, dimethyl sulfoxide (DMSO) and different terpenes may provoke lipid disorder 
in the stratum corneum  increasing the drug diffusivity (Moser et al., 2001).  
 
2) Increasing drug solubility in the skin. 
 
Agents typically thought to act in this way are propylene glycol, ethanol, Transcutol® 
and N-methyl pyrrolidone. 
Ethanol seems to enhance the solubility of some drugs both by increasing the apparent 
partition coefficient and by extraction of stratum corneum lipids. (Moser et al., 2001) 
Transcutol®  and some terpenes have also been investigated due to their potential to 
increase permeation by improving partitioning into the skin. 
 
3) Increasing the degree of saturation 
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1.2. The Eye. 
 
1.2.1. Ocular anatomy and physiology. 
 
Although it is small in size, the eye (Figure 4) provides us with the most important of 
the five senses: vision.  
Light enters the eye through the cornea. The cornea is spherically shaped and it forms 
the first and most important refracting surface due to the large change in index of 
refraction encountered from air to the corneal tissue. In a spectral sense it heavily 
attenuates optical radiation below 320 nm, such that at about 300 nm the eye is virtually 
opaque to optical radiation. Next, the light passes the aqueous humor, which is optically 
very transparent, except in the far infrared. The lens is another optically important 
component. It forms the second largest refracting element, and it further spectrally 
filters the light, mainly as an additional block of the short wavelengths that are 
dangerous to the retina. The lens is optically limited in size by the circularly shaped 
pupil, the diameter of which depends on the intensity of the light falling on the retina. 
Light passing the lens enters the vitreous, like the aqueous humor an almost optically 
transparent element. The refraction of light by both the cornea and the lens forms an 
image of the world outside at the retina. The lens can adjust its shape to have a sharp 
view nearby, or at a distance; a property called accommodation. This property decreases 
with age and is lost at middle age.  
The most important part of the eye is the retina, as it contains the light receiving 
elements, the cones and the rods. The cones are most densely packed in a central area 
used for vision with the highest acuity, called the fovea. A somewhat larger central area 
is called the macula. The rods are absent in the central fovea, but very abundant                   
in the peripheral retina. Linked to the spatially peaked cone distribution is a layer of a 
yellow substance, the macular pigment, which mainly consists of lutein and zeaxanthin. 
The main function of macular pigment probably is its antioxidant property in the fight 
against free radicals, generated by the combination of high oxygen tension and light. 
Optical effects are the spectral filtering of dangerous blue light passing the cornea and 
eye lens filters, and possibly, reducing chromatic aberration in this area of very detailed 
vision.  
The retinal pigmented epithelium (RPE) is a thin layer containing the pigment melanin, 
a substance with very strong light trapping properties. It screens the receptors at the 
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back side from stray light from deeper layers. The RPE is attached to Bruch’s 
membrane, a mechanically strong structure. The blood-brain barrier is formed by close 
contacts (so called tight junctions) between RPE cells. Posterior to Bruch’s membrane is 
first a thin fenestrated layer of blood vessels, the choriocapillaris. Apart from supplying 
nutrients, it also serves to stabilize the temperature in case of high levels of illumination 
absorbed by the RPE. The sclera is a very strong structure at the outside of the eye; it 
has a whitish appearance. Between the sclera and the choriocapillaris, we find the 
choroidal space filled with blood vessels, melanin particles, and tissue.  
 
 
 
 
 
 
 
Figure  4  Cross section of the human eye. 
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A brief description of the most important structures of the human eye is reported below: 
 
• Aqueous. A water-like fluid which fills the front part of the eye between the lens 
and cornea. This fluid is produced by the ciliary body and drains back into the 
blood circulation through channels in the chamber angle. It is turned over every 
100 minutes.  
• Chamber Angle. Located at the junction of the cornea, iris, and sclera, the 
anterior chamber angle extends 360 degrees at the perimeter of the iris. Channels 
here allow aqueous fluid to drain back into the blood circulation from the eye. 
May be blocked in glaucoma.  
• Choroid.  A very vascular layer between the sclera and retina which serves to 
nourish the outer portions of the retina. Has one of the highest blood flows in the 
body.  
• Ciliary Body. A structure located behind the iris (rarely visible) which produces 
aqueous fluid that fills the front part of the eye and thus maintains the eye 
pressure. It also allows focusing of the lens.  
• Conjunctiva. A thin lining over the sclera, or white part of the eye. This also 
lines the inside of the eyelids. Cell in the conjunctiva produce mucous, which 
helps to lubricate the eye.  
• Cornea. The clear window through which we see. Actually, this is a very vital 
part of the eye's focusing, and the curvature of the cornea itself accomplishes 
about 80% of the focusing of the eye.  
• Episclera. A fibrous layer between the conjunctiva and sclera. Sometimes lumps 
(pingueculum) will form in this layer on the surface of the eye near the inside or 
outside corners.  
• Extraocular Muscles. Six muscles control eye movement. Five of these originate 
from the back of the orbit and wrap around the eye to attach within millimeters 
of the cornea. Four of these move the eye roughly up, down, left and right. Two 
muscles (one originating from the lower rim of the orbit) control the twisting 
motion of the eye (when the head is tilted).  
• Iris. This is the part of the eye which gives it color. It contains muscles which 
open or close the pupil in response to the brightness of surrounding light. A blue 
iris actually has a lack of pigment.  
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• Lens. This is located just behind the iris, and helps to focus light. A "capsule" 
surrounds the lens "nucleus". The nucleus can become cloudy, and this is termed 
cataract.  
• Macula. The part of the retina which is most sensitive, and is responsible for the 
central (or reading) vision. It is located near the optic nerve directly at the back 
of the eye (on the inside). This area is also responsible for color vision.  
• Optic Nerve. This contains visual information from the eye, and has about 1.2 
million nerve fibers. The optic disc is visible on the inside of the eye, where the 
nerve is viewed "end on". The sheath around the optic nerve is continuous with 
that of the brain, and the nerve connects directly into the brain.  
• Orbit. The boney socket containing the eye, fat, extraocular muscles, nerves, and 
blood vessels. The floor and inside walls of the orbit are paper thin, and are 
easily fractured by trauma.  
• Pupil. Essentially, a hole in the iris. This is the black opening in the center of the 
eye. Its size is controlled by the iris muscles.  
• Retina. This thin layer lines the inside of the eye and receives light rays, 
processes them, and sends signals to the brain via the optic nerve. The retina is 
like the "film of a camera". It is separated from the very vascular choroid by the 
"retinal pigment epithelium". Sometimes breakdowns in this pigmented layer 
allow macular degeneration.  
• Sclera. The white, tough wall of the eye. Few diseases affect this layer. It is 
covered by the episclera and conjunctiva, and eye muscles are connected to this.  
• Uveal tract. A group of similar eye structures including the choroid, ciliary body 
and iris. May be prone to inflammatory conditions (uveitis or iritis).  
• Vitreous. A jelly-like, clear fluid which fills most of the eye (from the lens 
back). This tends to liquefy with age, and its separation from the retina can lead 
to retinal tears and detachment.  
 
 
1.2.2 Ophthalmic drug delivery systems. 
 
Ophthalmic drug delivery is one of the most interesting and challenging endeavors 
facing the pharmaceutical scientist. The anatomy, physiology, and biochemistry of the 
eye render this organ highly impervious to foreign substances. Development of newer, 
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more sensitive diagnostic techniques and novel therapeutic agents continue to provide 
ocular delivery systems with high therapeutic efficacy. Conventional ophthalmic 
solution, suspension, and ointment dosage forms no longer constitute optimal therapy 
for this indications.  
The specific aim of designing a therapeutic system is to achieve an optimal 
concentration of a drug at the active site for the appropriate duration. Ocular disposition 
and elimination of a therapeutic agent is dependent upon its physicochemical properties 
as well as the relevant ocular anatomy and physiology. A successful design of a drug 
delivery system, therefore, requires an integrated knowledge of the drug molecule and 
the constraints offered by the ocular route of administration. 
 
Nowadays, there are, on the market or undergoing clinical trials, ocular drug delivery 
systems to sustain drug release. Most of them are for the treatment of long-term diseases 
that affect the posterior segment of the eye. The important indications for ocular drug 
delivery systems include ocular degeneration, viral infections (like CMV infections), 
glaucoma, ocular inflammations, dry eye syndrome, and retinal degenerations. There are 
many important indications for ocular drug delivery systems depending on the site of 
application and the delivered drug. 
The challenge is to provide a system with improved ocular drug bioavailability and 
prolonged duration of activity, but still with a minimum risk of ocular complications 
(Table 2). The mode of administration plays  an important role in defining the safety of 
the device and further, in achieving patient compliance and acceptance. In general the 
highest risk of ocular complications is with invasive ocular drug delivery. The risk is 
smaller with periocular drug administration. When ocular complications are rare for the 
systemic drug administration, there is a prevalence of systemic adverse effects. 
 
 
Table 2  Classification of the routes for ocular drug administration 
Invasive drug administration to intraocular cavities 
? Intravitreal surgery (at the oars plana) 
? Repeated (*) intravitreal injections 
? Intracameral surgery (capsular bag) 
? Subretinal injections 
? Repeated (*) suprachoroidal injections 
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? Repeated (*) intracameral injections 
 
Invasive periocular and sclera modes of drug administration 
? Intrascleral surgery 
? Episcleral surgery 
? Repeated (*) periocular injections 
? Repeated (*) subconjuctival injections 
? Transscleral diffusion from controlled release systems 
 
Non-invasive methods 
? Topical administration on the eye 
 
Systemic administration 
? Intravenous infusion and injection 
? Per oral 
(*) The repetition is needed to accomplish long-term ocular treatment. (Del Amo and 
Urtti , 2008). 
 
 
1.2.3 Transcorneal drug absorption and vehicle effects. 
 
Owing to easy accessibility of the eyeball, topically applied drugs are widely employed 
in ophthalmology for both diagnostic and therapeutic purposes. 
In spite of a variety of defense mechanisms which protect the eye from noxious 
substances  in the environment (as the continuous secretion of tears which coats an 
impermeable surface epithelium), topical administration of drugs on the eyes surfaces 
allows persistence of therapeutic levels of medications for clinically effective durations 
of time and minimized unwanted collateral systemic effects, though these substances 
can rapidly spread to all parts of the body. 
On their way from the outside to the inside of the eye medications may encounter 
several obstacles 
The first impact is on the lachrymal film: the characteristics of tear distribution and flow 
greatly affect one of the most important factors involved in intraocular drug penetration. 
Contact-time may be prolonged by means of various techniques, such as increased 
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viscosity of drops or other engineered devices (e.g. viscous formulations, mucoadhesive 
formulations, in situ active gel-forming systems, inserts, shields systems or particulates) 
(Vincent H.L. Lee, 1990). However it is mainly influenced by the tear flow, which is 
known to be variable for different subjects and in different situations. 
As a general rule, the rapid washout with drops instilled into the conjunctival sac leads 
to immediate loss of a great part of the drug. 
In fact, the total volume of fluid the eye can hold being 10 µl, only about 20% of a drop 
delivered by commercial eye droppers (the volume of which is about 50 µl) can be 
retained by the eye. Additional loss of medications usually occurs since a faster 
turnover rate may result from reflex tearing caused by the irritation of the drop. 
The composition of tears includes various substances such as proteins, electrolytes, 
vitamins, enzymes, glucose  and others, which may play a rule in the transfer of drugs to 
the cornea. 
In normal conditions when the eye is open the lachrymal fluid  is divided  into three 
separate compartments: a) the pre-corneal film which covers the exposed cornea and 
conjunctiva; b) a mostly stagnant layer moistening the conjunctiva under the lids; c) the 
marginal tear strips along which the tear flow occurs. 
The pre-corneal film in turn is composed of three layers: the superficial oily layer is 
primarily derived from the meibomian glands and restricts the evaporation of the 
underlying  watery layer which is mostly produced by the lachrymal glands. The 
innermost mucoid layer is derived from the conjunctival  globet cells and is effective in 
stabilizing the tear film. 
During a blink the mucin layer is spread over the cornea,  thus maintaining its normal 
wetting and producing a hydrophilic surface for the tear film. 
Drugs dissolved in the lachrymal film penetrate the globe almost exclusively through 
the cornea, most of the material which crosses the conjunctiva being rapidly lost to the 
blood stream, and only small portions diffusing through the limbal zone and the sclera. 
In fact the conjunctival epithelium acts as a barrier against penetration of substances 
under the conjunctiva, but it appears to be weaker than the corneal epithelium. When in 
the sub-conjunctival space, drugs are rapidly lost to the blood before having the 
possibility to penetrate the deeper tissues. This could give reason for unpleasant 
systemic side effects sometimes occurring after instillation of drugs into the 
conjunctival sac, and for reduces therapeutic efficacy of topical medications in diseases 
affecting the back of the eye. 
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The cornea may act as a pathway, a barrier or a reservoir of drugs. Of the five layers in 
which the cornea is classically divided, only the sandwich consisting of the stromal 
connective tissue covered by the epithelial and endothelial cellular layers is relevant to 
trans-corneal drug penetration. The barrier is mainly represented by the epithelium,  the 
reservoir by the stroma (particularly for hydrophilic substances), while the role of the 
endothelium is negligible for both aspects. 
The epithelium and the endothelium, rich in lipids and cells, are mostly permeably to 
substances possessing a fat-soluble phase, while the stroma, characterized by relative 
acellularity and a high water content, is mostly permeable to substances possessing a 
water-soluble phase. Therefore, to be able to pass through the intact cornea, substances 
must be soluble in both fats and water, since purely water-soluble substances cannot 
penetrate the epithelium and purely fat-soluble substances cannot penetrate the stroma. 
Epithelium occupies about 10% of total corneal thickness and is composed of five to six 
layers of cells, increasing to eight to ten at the corneal periphery. 
Three groups of cells are usually identified in the epithelium: a single row of basal cells, 
an intermediate zone of two or three layers of polygonal cells (wing cells), and a couple 
of superficial layers of large, flattened cells, which are characteristically joined by tight 
junctions, and present surface microplicae and microvilli which could play a role in the 
retention of pre-corneal film. The barrier effect of corneal epithelium is mainly due to 
the presence of tight junctions, which probably represent the most difficult hurdle to 
penetration of ionic solutes. 
In fact  the dissociated ions such as Na+ and Cl- pass the cellular layers slowly through 
the paracellular pathway,  like other ionized substances (as for example fluorescein).  
The arrangement of superficial epithelial cells leads to an increase of the path distance, 
owing to flattening and overlapping of these cells, the large diameter of which allows 
relatively few intercellular spaces which open on the outer surface of the cornea. 
Undissociate salts on the other hand are fat-soluble and can pass more rapidly through  
cell membranes (Saettone et al., 1987). 
 
The fat solubility of the substance depends, among other factors, on its non-polar 
nature, i.e. on possessing an extremely symmetric atomic structure. These substances 
therefore penetrate more rapidly into the eye when the epithelium is intact than when  it  
is disrupted or absent (the contrary, of course, occurring with water-soluble substances). 
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The permeability of corneal epithelium to different substances varies considerably 
according to their dissociation, which is mainly dependent upon the hydrogen ion 
concentration (pH) of the solution in which they are dissolved. 
Moreover epithelial permeability has been shown to decreased in anoxic conditions, as 
can occur in patients using extended wear contact lenses. (Saettone et al., 1987). 
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1.3 Alkanoyl-6-O-ascorbic acid esters 
 
Ascorbic acid and its derivatives play an important role in many biological processes as 
reducing agents or radical scavengers. Triplet excited state carbonyl compounds react 
with ground state oxygen to give the highly reactive singlet excited molecular oxygen, 
that reacts with proteins, nucleic acids, and cellular lipids, and induce severe damages in 
biological systems . When water is exposed to ionizing radiation, different radicals are 
formed, such as .OH and .OOH. The current increment of radical species in the 
atmosphere (particularly nitrogen oxides), the seasonal partial loss of the ozone layer, 
and the increase of the ultraviolet irradiation over the Earth, justify the importance of 
using antioxidant species in protecting terrestrial life from free radicals’ attack, or in 
minimizing their dangerous activity. 
Cellular protection against singlet oxygen damage may be granted by a number of 
quenchers, such as ascorbic acid, carotenoids and phenols, notably tocopherols. 
Ascorbate behaves as a weak singlet oxygen quencher, it is, in fact, a better one-electron 
reductant  than tocopherol ( E°’= +0.23 V). Its lipophilic derivative 6-O-ascorbyl-
palmitate is a good antioxidant in model systems and is also effective in cellular 
systems or against Epstein-Barr virus activation. The presence of one or more 
hydrophobic chain in vitamin C-based surfactants leads to the formations of 
supramolecular self-assembled aggregates in water, such as micelles, where an inner 
lipophilic core is surrounded by a hydrophilic shell made up of the polar headgroups 
(Palma et al., 2002a). 
 
 
1.3.1 Physicochemical propierties of ASCn  
 
Alkanoyl-6-O-ascorbic acid esters were synthesized in order to transfer the peculiar 
properties of vitamin C in lipophilic media. Since  a hydrophobic portion (aliphatic 
chain) and a polar group (ascorbic acid) are present in their structure, these  esters 
behave as anphiphilic molecules but,  due to their low water solubility, their use as 
surfactant agents is limited, especially when the side tail is a long hydrocarbon chain 
(more than ten carbon atoms) and at low temperatures. When the surfactant 
concentration reaches the critical micellar concentration (CMC) value, solubility 
increases, due to the formation of supramolecular  aggregates and the solubilization of 
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monomers in these structures (Palma et al., 2007). Further addition of monomers to a 
micellar dispersions increases the number of the supramolecular aggregates, and may 
result in structural (shape and size) changes, while the monodispersed amphiphiles 
concentration remains unchanged. The temperature dependence of surfactans solubility 
indicates the existence of the so-called Krafft temperature or Krafft point (CMT) 
(Myers, 1994; Clint, 1992).  
 
 
 
 
R = (CH2)x – CH3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once the CMT has been reached (Table 3), cooling down the sample results in the 
formations of a liquid crystal, and a semisolid viscous system known as “coagel” is 
obtained, due to the little hydration of the aggregates (micelles, lamella and vesicles). 
 
 
 
 
 
Figure 5. a-Schema of ASCn  derivative; b- Structure of ASCn 
 
 
a b
x        ASCn 
 
6     ASC 8 
8     ASC 10 
9     ASC 11 
10   ASC 12 
12   ASC 14 
14   ASC 16 
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Table 3: Melting point and TMC of ASCn aqueous dispersions  
 
Compound                    Melting point (°C)                           TMC(°C) 
 
ASC8                             87.0-88.0                                          18.5 
ASC10                           96.0-98.0                                          34.5 
ASC12                         105.0-106.5                                        47.3 
ASC14                         108.0-109.0                                        56.0 
ASC16                         113.0-114.0                                        63.8           
 (from Palma et al, 2002a) 
 
 
 
Structural differences of coagels can be tracked also at a microscopic level. Figure 6 
shows the ESEM micrographs of coagels from ASC8, ASC10, ASC12 and ASC16. For 
ASC8 and ASC10, the coagel structures can be depicted as a planar continuous lamellar 
phase, where bilayers are ordered in sheets. However, important size differences in the 
plates are observed (see Figure 6a and 6c) (Palma et al., 2003a). 
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In  Fig 7, where are shown shear rate vs. shear stress flow curves, the rheological 
behavior of the coagels is reported. All coagels show a non-Newtonian flow. The 
differences are directly related to their structure. 
 
 
Figure. 6. ESEM for ASCn coagels.  
 22
 
 
 
 
 
 
 
 
Coagels from ASC10 and ASC11 (Figure 7b and c) showed pseudo-plastic flow and in 
the case of ASC11 thixotropy was detected as well. 
Conversely, coagels from ASC8, ASC12, ASC14 and ASC16 exhibit a much more 
complex rheology (Figure 7a,d–f). The rheograms form a hysteresis loop in which the 
‘down’ curve is displaced to the left of the ‘up’ curve. A characteristic feature of many 
such rheograms is the presence of a ‘spur’ point on the ascending curve. The rheology 
of these coagels displays a high yield or “spur” value. This can be taken as a measure of 
the strength necessary to break the ordered structure of the system before a significant 
flow occur. The shear stress at spur point is called the ‘static yield value’ (σS). For such 
systems an irreversible structure breakdown is observed when the shear stress exceeds 
σS. When the spur value is reached, the secondary structure of coagels is broken and 
ASC12, ASC14 and ASC16  coagels acquire pseudo plastic flow (Palma el at, 2007). 
Figure. 7  Rheograms for ASCn coagels: (a) ASC8; (b) ASC10; (c) ASC11; (d) ASC12; 
(e) ASC14; and (f) ASC16.  
 23
 
Coagels from ASC12, ASC14 and ASC16 have a rheological behavior similarly to ASC8 
samples. However, ESEM images ( Figure 6e–h) show a very different arrangement of 
the lamellae that form a ‘house of cards’ structure. Swelling and strengthening of the 
semisolid network is owed to the presence of strongly bound water regions between the 
amphiphilic bilayers. On the contrary, for ASC10 and ASC11 coagels, this kind of 
arrangement is apparently not possible. When coagels of ASC12, ASC14 and ASC16 are 
subjected to shear stress (τ>σS), the structure breaks irreversibly and the viscosity 
decreases significantly. The sample acquires a less ordered pattern, similar to that of 
ASC10. Figure 7f indicates that the ASC16 coagel acquires a pseudo plastic behavior 
after shear stress as in the case of ASC10 and ASC11 coagels. Such rheology is a 
characteristic feature of some coarse systems commonly used in pharmacy. 
 
The spur value can be changed with the addition of compounds as polyethylen glycol 
400 (PEG 400) (Saino et al., 2004). Increasing the amount of PEG 400 doesn’t produce 
changes in the rheological behavior of ASC16, as shown in Figure 8 where flow curves 
(shear rate vs shear stress) are reported. Furthermore it is evident from rheograms 
profile that the spur values is present in every curve and σS become higher increasing 
the amount of PEG 400, owing to the co-solvent improvement of coagel structure. 
 
 
 
 
 
 
 
 
                                            
 
 
  Figure 8  Rheograms for ASC16 coagels with PEG400 10, 30, 50 and 70 % w/w.  
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1.3.2 In vitro permeation of ASCn and influence in drug absorption (enhancement 
properties) 
 
The permeation of ASCn (ASC12 and ASC16) and its effect on “in vitro” and “in vivo” 
drug (Anthralin, ANTH) diffusion through rat skin were evaluated (Palma et al., 2006).  
Penetration of ASCn through rat skin epidermis was very fast and quantitatively 
significant. ASC12 appears to be the compound that possesses the highest capacity to 
enhance the penetration of the drug maybe because of self-penetration through the 
epidermis. The ability of these compounds to permeate the rat skin is related to their 
chemical composition, since the flux of ASCn decreases as alkyl chain length increases. 
Furthermore, a burst effect was observed with ASC12. 
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1.4.  Ibuprofen: Technological aspects. 
 
Ibuprofen (IBU) is a potent non-steroidal anti-inflammatory (NSAID) drug often used 
for the treatment of acute and chronic arthritic conditions (Busson, 1986). IBU can 
cause gastric mucosal damage which may results in ulceration. For this reason in past it 
was interesting to develop topical dosage forms of IBU. Indeed, many new topical 
formulations of IBU have been studied and evaluated in order to increased the 
bioavailability of the drug and minimized the side effects. Topical drug delivery of IBU 
in various formulations has been described (Muktadir et al.,1986; Chang et al., 1997; 
Cilurzo et al., 2005).  
In the experimental work of Yun-Seok Rhee et al., (2008), the in vitro IBU permeation 
from several topical formulations through hairless mouse skin was studied. The three 
factors chosen for the factorial design were the concentration of the drug, of 
polyoxyethylene(5)cetyl/oleyl (POE(5)cetyl/oleyl) ether and of ethanol; the level of 
each factor was low, medium and high. The permeation rate of IBU significantly 
increased in proportion to the drug concentration, but decreased in proportion to 
POE(5)cetyl/oleyl ether concentration. Ethanol concentration was inversely proportional 
to the lag time.  
In another experimental work (Herkenne et al., 2006) the effect in vivo of propylene 
glycol (PG) on IBU absorption through human skin, was studied. IBU Formulations 
with several amounts of PG (from 0 to 100 % v/v), a common co-solvent in topical 
formulations, were assessed by tape-stripping. Dermatopharmacokinetic parameters, 
characterizing drug amount in and diffusivity through the stratum corneum (SC), were 
derived. The solubility of the drug increased when the PG concentration increased, the 
values of viscosity increased in formulations with higher co-solvent concentration, but 
PG did not affect the diffusivity of the IBU across the SC.  
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1.5. Diclofenac: Technological aspects. 
 
 
Diclofenac (DICH), an NSAID, has been found to be a viable alternative to steroids in 
treating ocular inflammation. It has poor aqueous solubility. Aqueous solutions of 
DICH sodium (DICHNa) commonly applied topically in the eye were 0.1% w/v. A 
major impediment to the bioavailability of topically applied ophthalmic drugs is 
incomplete absorption due to nasolacrimal drainage ( Ahuja et. al, 2007). 
To overcome this, several dose ophthalmic forms have been studied to maximize the 
amount of the DICH in the site of action. Attama (2007) studied the delivery of 
DICHNa to the eye using bio-engineered human cornea from solid lipid nanoparticles 
(SLNs) prepared with a combination of homolipid from goat (goat fat) and 
phospholipid. Results obtained in this work showed that permeation of DICHNa 
through the cornea construct was improved by formulation as SLN modified with 
phospholipids. In another work,  Valls et al., (2008), tested different formulations of 
DICHNa and demonstrated that corneal permeation was remarkably enhanced when 
diclofenac was formulated as a ß-cyclodextrin complex. 
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2. Materials and methods 
 
2.1. Chemicals  
 
Palmitoyl-6-O-ascorbic acid or ascorbyl palmitate (ASC16), L-ascorbic acid (AA), 
Anthralin (Anth), Griseofulvin (Gris), S-(+)-Ibuprofen (IBU), Diclofenac acid (DICH), 
lauric acid (LA), polyethylen glycol 400 (PEG 400), sodium lauryl sulphate (SLS) and 
disodium hydrogen phosphate (Na2HPO4) were purchased from Fluka (Milan, Italy), 
their purity was 99% according to the manufacturer. Lauroyl-6-O-ascorbic acid or 
ascorbyl-laurate (ASC12) was synthesized in our laboratories according to the procedure 
already reported in literature (Capuzzi, 1996).   
Sulfuric acid 95%, diethyl ether, petroleum ether, and sodium sulphate (analytical 
grade) were purchased from Fluka (Milan, Italy) and used without purification. 
D(+) glucose monohydrate (Glu), methanol (MeOH), acetonitrile (AcN), isopropyl 
alcohol  both of HPLC-grade, were purchased from Carlo Erba (Milan, Italy). Milli-Q 
water was used in all experiments. 
A commercial gel containing 10% w/w of ibuprofen lysine  (Arfen®, Lisapharma, 
Erba, CO, Italy) was used as references in the permeation study through hairless rat 
skin, and the commercial Voltaren Ophta® (Ciba Vision) was used as reference in the  
ocular pharmacokinetics tests. 
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2.2. Pharmacological aspect  of the drugs  
 
2.2.1 Dithranol (ANTH) 
Dithranol or Anthralin, 1,8-dihydroxy-9,10-dihydroanthracen-9-one (C14H10O3) , is  a 
hydroxyanthrone, anthracene derivative, medicine applied to the skin of people with 
psoriasis. It is commercially available as 0.1 to 2% w/w/ creams, ointment or pastes. 
Dithranol has a slower onset of action in controlling psoriasis, typically several weeks, 
compared to glucocorticoid steroids, but is without the potential for rebound reaction on 
withdrawal. Dithranol accumulates in mitochondria where it interferes with the supply 
of energy to the cell, probably by the oxidation of dithranol releasing free radicals. This 
impedes DNA replication and so slows the excessive cell division that occurs in 
psoriatic plaques. In addition Dithranol may act by reducing the elevated levels of 
cGMP that occurs in psoriasis.  
The application of Dithranol formulation temporarily stains the skin a yellowy-brown. 
It may cause a local burning sensation and irritation, this may be minimised by careful 
attention to the details of treatment and only gradually stepping up through the 
strengths of dithranol formulations.. 
 
 
 
 
 
Figure 9 -  Structure of ANTH 
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2.2.2. Diclofenac  (DICH) 
 
Diclofenac,  2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid (C14H11Cl2NO2) is a 
non-steroidal anti-inflammatory drug (NSAID) with  inflammatory  and analgesic 
properties, reducing pain in conditions such as arthritis or acute injury. 
There is some evidence that diclofenac inhibits the lipoxygenase pathways, thus 
reducing formation of the leukotrienes (also pro-inflammatory autacoids). There is also 
speculation that diclofenac may inhibit phospholipase A2 as part of its mechanism of 
action and these additional actions may explain the high potency of diclofenac. 
The action of one single dose is much longer (6 to 8 hours) than the very short half-life 
that the drug indicates. This could partly be due to a particular high concentration 
achieved in synovial fluids. 
Diclofenac is used for musculoskeletal complaints, especially arthritis (rheumatoid 
arthritis, osteoarthritis, spondylarthritis, ankylosing spondylitis), gout attacks, and pain 
management in case of kidney stones and gallstones. An additional indication is the 
treatment of acute migraines.  
As long-term use of diclofenac and similar NSAIDs predisposes for peptic ulcer, many 
patients at risk for this complication are prescribed a combination of diclofenac and 
misoprostol, a synthetic prostaglandin analogue, to protect the gastric mucosa. 
An external, gel-based formulation containing 3% of diclofenac is available for the 
treatment of facial actinic keratosis which is caused by over-exposure to sunlight. Some 
countries have also approved the external use of diclofenac 1% gel to treat 
musculoskeletal conditions. 
The use of diclofenac is not indicated in the case of hypersensitivity against the drug, in 
patient with history of allergic reactions (bronchospasm, shock, rhinitis, urticaria) 
following the use of Aspirin or another NSAID or in patient with active stomach and/or 
duodenal ulceration or gastrointestinal bleeding, inflammative intestinal disorders such 
as Crohn's disease or ulcerative colitis and severe insufficiency of the heart (Goodman 
& Gilman, 2006). 
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Figure  10  - Structure of DICH 
 
 
 
2.2.3 Griseofulvin (GRIS) 
 
 
Griseofulvin, (2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-
2,1'-cyclohexan]-2'-ene-3,4'-dione, is an antifungal drug. It is used both in animals and 
in humans, to treat ringworm infections of the skin and nails. The drug binds to tubulin, 
interfering with microtubule function, thus inhibiting mitosis. 
It binds to keratin in keratin precursor cells and makes them resistant to fungal 
infections. It is only when hair or skin is replaced by the keratin-griseofulvin complex 
that the drug reaches its site of action. Griseofulvin will then enter the dermatophyte 
through energy dependent transport processes and bind to fungal microtubules. This 
alters the processing for mitosis and also underlying information for deposition of 
fungal cell walls. 
Known side effects of griseofulvin include: hives, skin rashes, confusion,  dizziness, 
diarrhea, fatigue, headache, nausea and vomiting (Goodman & Gilman, 2006). 
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    Figure 11  -  Structure of   GRIS 
 
 
 
2.2.4 Ibuprofen (IBU) 
 
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) originally marketed as 
Brufen and used as an analgesic and anti-inflammatory for relief of symptoms of 
arthritis, primary dysmenorrhea, fever. Ibuprofen is a core medicine in the World 
Health Organization's "Essential Drugs List", which is a list of minimum medical needs 
for a basic health care system. 
Low doses of ibuprofen (200 mg, and sometimes 400 mg) are available over the 
counter (OTC) in most countries. Ibuprofen has a dose-dependent duration of action of 
approximately 4–8 hours, which is longer than suggested by its short half-life. 
Ibuprofen is an NSAID which is believed to work through inhibition of cyclooxygenase 
(COX), thus inhibiting prostaglandin synthesis. There are at least 2 variants of 
cyclooxygenase (COX-1 and COX-2). Ibuprofen inhibits both COX-1 and COX-2. It 
appears that its analgesic, antipyretic, and anti-inflammatory activity are achieved 
principally through COX-2 inhibition; whereas COX-1 inhibition is responsible for its 
unwanted effects on platelet aggregation and the GI mucosa. The role of the individual 
COX isoforms in the analgesic, anti-inflammatory, and gastric damage effects of 
NSAIDs is uncertain and different compounds cause different degrees of analgesia and 
gastric damage. 
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Ibuprofen appears to have the lowest incidence of gastrointestinal adverse drug 
reactions of all the non-selective NSAIDs. However, this only holds true at lower doses 
of ibuprofen. 
Common adverse effects include: nausea, dyspepsia, gastrointestinal 
ulceration/bleeding, raised liver enzymes, diarrhea, epistaxis, headache, dizziness, 
unexplained rash, salt and fluid retention, and hypertension. (Goodman & Gilman, 
2006). 
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2.3 Methods  
 
 
2.3.1 Synthesis of ascorbyl-laurate  
 
Ascorbyl laurate (ASC12) was synthesized by condensation reaction between lauric acid 
(LA) and C6OH primary group of L-ascorbic acid  in  sulfuric acid  at 45°C (Capuzzi,   
1996).  A 100 ml sample of 95% sulfuric acid was placed in an Erlenmeyer flask, and a 
gentle stream of nitrogen was passed for 30 min under magnetic stirring at room 
temperature. Then, ascorbic acid (4.41 g, 25 mmol, AA) was completely dissolved and 
after LA (5.01 g, 25 mmol) was added. The flask was then equipped with a rubber 
stopper and kept in a nitrogen atmosphere. A water bath at 45°C was used to dissolve 
LA completely. After 16 h, the mixture was poured into a beaker containing 600 ml of 
ice and stirred until it reached room temperature. The solution was treated with diethyl 
ether several time, after the organic phase was treated with anhydrous  sodium sulfate 
for 30 min and then filtered. The white-yellow solid was obtained after evaporation 
under reduced pressure of the solvent  which was washed in petroleum ether and finally 
recrystallized three times from diethyl ether/petroleum ether (50:50)  mixtures.  
 
 
2.3.2 Characterization of ascorbyl-laurate  
 
Purity  was conveniently assessed through TLC and chemical-physical analysis. TLC 
(silica  gel, diethyl ether): only one spot with Rf= 0.41 was observed. The melting point 
was 104.5-105.5°C , and the UV-VIS spectroscopy showed an assorbance at λ max,= 
236 nm (CH3CN) for an ASC12 organic solution.  
The ASC12 was characterized after preparation of a 2% w/w aqueous dispersion  
measuring the critical micellar temperature (CMT) by DSC analysis.  
DSC analysis was carried out using a  Pyris DSC6 differential scanning calorimeter 
(Perkin-Elmer), connected to an MC480 cooler circulator (FTS, Stone Ridge, NY, 
USA), using airtight closed aluminum pans. The critical micellar temperature (CMT) 
was taken as the temperature of the endothermic peak obtained for  a 10% w/w aqueous 
dispersion of ASC12 (ASC12/C).  
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The preparation of ASC12/C was reported in  section 2.3.3. and its composition was 
indicated in Table 4. 
 
 
2.3.3 Characterization of the ascorbyl-laurate by differential scanning calorimetry 
(DSC) 
 
The critical micellar temperature (CMT) for ASC12 was obtained through DSC runs 
with a Pyris DSC6 differential scanning calorimeter (Perkin-Elmer), connected to an 
MC480 cooler circulator (FTS, Stone Ridge, NY, USA), using airtight closed 
aluminum pans. The CMT was taken as the temperature of the endothermic peak 
obtained for 10% w/w aqueous dispersion of ASC12. 
Coagel was prepared by heating  10% w/w of ASC12  aqueous suspensions above its 
phase transition temperature (CMT = 47.3 °C, ASC12, Palma, 2003b) until the gel 
phase was formed. Then, it was permitted to reach room temperature to obtain the 
ASC12  coagel (ASC12/C).  
 
2.3.4 Characterization of the formulations by rheological measurements 
 
The rheological measurements  were carried out on the coagels  prepared without , and 
on the “disrupted coagels”, characterized by a structure  where the typical  form as 
“house of cards” was broken (Palma et al., 2003a).  The composition of the  analyzed 
formulations are reported in Table 5. 
Rheological assays were performed using a Haake RS1 Rheometer, equipped with the 
cone plate combination ( C60/4°) on a samples placed into the sensor plate and kept for 
5 min at 20°C. 
The measurements were carried out  between  0 and  200 s-1 in 300 s.  Data were 
acquired and analyzed by the Rheo Win Pro software (Haake). 
 
 
Preparation of samples analyzed.  
• Coagels were prepared by heating aqueous suspensions containing  2% w/w of 
ASC12 and ASC16 and glucose mono hydrate (5% w/w) above their phase transition 
temperature (CMT = 47.3 °C, ASC12;  63.8 °C, ASC16, Palma , 2003b) and adding 
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DICH (0.1% w/w) until the gel phase was formed. The systems were kept to of over 
TMC for 2 hours in order to obtain the complete solubilization of the drug, and then, 
they were permitted to reach room temperature to obtain the respective ASC12 and 
ASC16 coagels (ASC12/CGDich and ASC16 /CGDich). Glucose mono hydrate was 
added to obtain  isotonic formulations.  
Coagels without DICH but containing Glucose (ASC12/CGlu and ASC16/CGlu) and 
coagels  without DICH and Glucose  (ASC12/C(2%) and ASC16 /C(2%)) were 
prepared using the same method and used as  references in the ocular pharmacokinetic 
studies. 
 
• Coagels were prepared by heating aqueous suspensions containing 5% w/w of 
ASC12 and ASC16 above their phase transition temperature (CMT = 47.3 °C, ASC12;  
63.8 °C, ASC16, Palma, 2003b) and adding Ibu (0.85% w/w) until the gel phase was 
formed. The systems were kept to of over TMC for 2 hours in order to obtain the 
complete solubilization of the drug. Then, they were permitted to reach room 
temperature to obtain the respective ASC12 and ASC16 coagels (ASC12/CIbu and 
ASC16 /CIbu). Coagels without Ibu (ASC12/C(5%) and ASC16 /C(5%)) were prepared 
using the same method and used as references in the cutaneous permeation studies. 
 
• “Disrupted coagel” coagel was prepared by heating  a 5% w/w ASC16  aqueous 
suspension above their phase transition temperature (CMT =  63.8 °C, ASC16, Palma., 
2003b) and adding Ibu (0.85% w/w) until the gel phase was formed. The system was 
kept to of over TMC for 2 hours in order to obtain the complete solubilization of the 
drug, and then, it was permitted to reach room temperature with stirrer (600 rpm) to 
obtain the ASC16 disrupted  coagel (ASC16/Ibu).  
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2.4 Effect of  polyethylen glycol 400 (PEG 400)  on the solubility  of Anthralin and 
Griseofulvin. 
 
 
The evaluation of the effect of different amount of cosolvent (PEG 400)  on the 
solubility of  ANTH and GRIS in presence or in  absence of ASC16  were performed by 
UV–VIS measurements in the range of  200–400  nm at 25°C.   
 
 
2.4.1. Preparation of the formulations containing PEG 400. 
 
 An excess amount of drug was added to 5 ml water containing or not 2% w/w of 
ASC16 (ASC16PEG400 /C(2%)  and PEG 400 respectively),  with increasing amounts 
of PEG 400  (10 30, 50 and 70 % w/w). The preparations were shaken for 3 h in a  
water bath above their phase transition temperature (CMT =  63.8 °C, ASC16, Palma, 
2003b).  
After equilibrium was reached, suspensions were centrifuged at 13000 rpm  for 10 min 
to remove un-dissolved drug. An aliquot from each solution was adequately diluted 
with ethanol   ( 1: 20 ratio) and analyzed  at 365 and 324  nm  for ANTH and  GRIS 
respectively  (UV–VIS  Shimadzu UV-160 spectrophotometer). The experiments were 
carried out in triplicate (Palma et al., 2003c). 
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2.5 Evaluation of the stability of ASC16 coagels 
 
To evaluate the chemical stability of  ASCn derivatives after preparation of Coagels  a 
preliminary study was performed  on a  formulation containing  2% w/w ASC16 
derivative  alone and  in presence of   8 % w/w of Vitamin E, as antioxidant (Spiclin P. 
et al., 2001). 
 
 
2.5.1. Preparation of the coagels  for the preliminary evaluation of ASC16 derivate 
stability 
 
Coagels were prepared  by heating  2% w/w ASC16 aqueous dispersions, with and 
without Vit.E (8% w/w) in a  water bath above their phase transition temperature (CMT 
=  63.8 °C, ASC16 ) for about 120 minutes. Then the samples were kept to room  
temperature to obtain ASC16/C(2%) and ASC16/C(2%)VitE.  
The composition of the preparations were reported in Table 6. 
Aliquots of both formulations were maintained in closed vials at room temperature 
(RT) and 60° C and at predetermined times the samples were submitted, after 
appropriate dilution with methanol to HPLC analysis for quantitative analysis of ASC16 
derivatives. The HPLC method was reported in section 2.5. 
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2.6 Analytical method  
 
 
2.6.1 Chromatographic apparatus  
 
The amount of ASCn derivatives,  IBU and DICH in the formulations and in the 
different experimental samples  were assayed by HPLC.  
The chromatographic system  consisted of a LC 6A Pump, SPD-10A array detector and 
computer integrating system (Shimadzu Corp., Kyoto, Japan). The column (150 x 4 
mm) was C18 Synergi 4μm Fusion–RP 80A (Milford, MA, USA) to analyzed ASCn 
derivatives and IBU. The column used to analyze DICH samples was a C18 Bondclone 
10μm (30 cm x 3.9 mm, Phenomenex). The mobile phase was filtered, in all cases, 
through a 0.45 μm filter (Millipore™ Durapore) and degassed by vacuum prior to use. 
The different conditions, mobile phase, flow rate, retention time and wavelength are 
reporter in the Table 7. 
 
Preparation of standard solutions 
A stock standard solutions of ASCn (SS/ASCn), IBU, (SS/Ibu) and DICH  (SS/Dich) 
were  prepared by solubilization in methanol of an appropriate amount of each product  
exactly weighed. Then, several dilutions  in of isotonic buffer phosphate solution pH 
7.4 were prepared and injected (20 μl) into the HPLC using a manual system. 
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Table 7.  HPLC condition 
 
 
Compound 
 
 
Mobile phase 
(ratio) 
 
flow-rate 
(ml/min) 
 
Retention 
time 
(min) 
 
Wavelength 
(nm) 
 
ASC12 
ASC16 
MeOH:CH3CN: 
phosphate buffer 0.05M 
adjusted to pH 2.5 with 
phosphoric acid 
(65:14:21) 
 
 
1.0 
 
13.5 (ASC12) 
22.5 (ASC16) 
 
 
 
265 
 
 
IBU 
MeOH:CH3CN: 
phosphate buffer 0.05M 
adjusted to pH 2.5 with 
phosphoric acid 
(65:14:21) 
 
 
1.0 
 
 
4.2 
 
 
225 
 
 
DICH 
MeOH:CH3CN: 
phosphate buffer 0.05M  
adjusted to pH 7.4 with 
phosphoric acid 
(46:13:41) 
 
 
1.2 
 
 
8.5 
 
 
273 
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2.7 Preparation of the formulations for ex vivo skin permeation study of ibuprofen 
 
 
Preparation coagels (ASC12/CIbu and ASC16 /CIbu). 
Coagels were prepared by heating  at 52°C and 68°C a 5% w/w of ASC12 and ASC16  
aqueous suspensions above their phase transition temperature (CMT = ASC12: 47.3 °C,  
(ASC16,: 63.8 °C; Palma , 2003b) and adding IBU (0.85% w/w) until the gel phase was 
formed. The systems were kept over TMC for 2 hours in order to obtain the complete 
solubilization of IBU, and then, they were permitted to reach room temperature to 
obtain the respective ASC12 and ASC16 coagels (ASC12/CIbu and ASC16 /CIbu). The 
composition of the preparations were reported in Table 8. 
 
Preparation of  coagel based on ASCn with PEG 400  (ASC12 PEG400/CIbu and ASC16 
PEG400/CIbu). 
Coagels were prepared  the method previously reported  but adding  in the aqueous 
suspensions of ASCn the PEG 400 30% w/w to obtained the final formulations ASC12 
PEG400/CIbu and ASC16 PEG400/CIbu. The composition of the preparations were 
reported in Table 8.  
 
Preparation of  “Disrupted coagel“,  based  on  ASC16  ( ASC16 /Ibu)  
Coagels were prepared by heating  (5% w/w of  ASC16  aqueous suspensions above its 
phase transition temperature (CMT =  63.8 °C, ASC16, Palma, 2003b) and adding Ibu 
(0.85% w/w) until the gel phase was formed. The systems were kept to of over TMC 
for 2 hours in order to obtain the complete solubilization of the drug, and then, they 
were permitted to reach room temperature with stirrer (600 rpm) to obtain the  ASC16 
with its structure disrupted (ASC16/Ibu).  
 
Preparation of the reference suspension  based on PEG 400 (PEG-D) 
A suspension  based on 0.85 %  w/w of Ibu  (PEG-D) was prepared in a mixture 
constituted with PEG 400 30% in water. The suspension was maintained under 
magnetic stirrer for  hour  at room temperature. 
The composition of the suspension was reported in Table 8. 
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Preparation of the reference solution (Ibu-S) 
A solution containing  0.85 w/w  Ibu (Ibu-S) prepared by dissolving Ibu in a mixture  
isopropanol/pH 7.4, 66.7 mM phosphate buffer (20:80 ratio) under magnetic stirrer and  
it was used as reference. The composition was reported in Table 8. 
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2.8 .In vitro release of Ibuprofen from coagels.  
 
The  in vitro release of ibuprofen from coagels ASC12/CIbu, ASC16 /CIbu, 
ASC16PEG400/CIbu, ASC12PEG400/CIbu  and from the reference formulations (Ibu-
S, PEG-D, , and  Arfen
®
)  was assessed using dialysis bags (cut off=3000- 3500 Da) 
filled with a fixed amount of each formulation (about 10.0 g). The bags were put into  
10.0 ml of  isotonic buffer phosphate solution 66.7 M, pH 7.4 (receptor phase). The 
receptor phase was stirred and thermostated at 37 °C. At fixed time 1.0 ml of the 
receptor phase were withdrawn and replaced with fresh fluid. The drug released was 
assayed by HPLC.  
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2.9. Ex  vivo permeation of Ibuprofen through hairless rat skin 
 
Permeation tests of Ibu were performed using  excised skin of 6-8 week-old hairless rat 
(OFA-hr/hr, Charles River Italia SpA). The animals were killed by cervical dislocation 
immediately before the experiments, the skin was carefully excised and the adhering fat 
and subcutaneous tissue were removed. 
The perfusion apparatus consisted of Gummer-type diffusion cells with an available 
diffusion area of 1.23 cm2  and stratum corneum facing the donor compartment (Monti 
et al., 2002). The donor phase consisted  of  about  1.0 g of coagels (ASC12/CIbu , 
ASC16/CIbu, ASC16 PEG/CIbu and ASC12PEG/CIbu),  or  Ibu-S, ASC16 /Ibu and  of  
0.14 ml of Arfen®.  The dose of  drug used for the  experiment was corresponding to  
8.5 mg  of IBU 
The receiving compartment contained 5.0 ml of receiving isotonic 66.7 mM pH =7.4 
phosphate buffer solution maintained at 37°C and stirred at 600 rpm. At predetermined 
intervals of  time, 5.0 ml samples of receiving phase were withdrawn for HPLC 
analysis and replaced with the same volume of fresh fluid. All experiments lasted 20 
hours and were performed four times (Tampucci,  2005). 
 
      
 
 
 
 
 
 
 
 
 
Figure 12.-  Schema of the cell Gummer type. (1,2: receiving phase;  3,4: thermostated 
water). 
 
 
 
 
1 
2 
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3 
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 2.10. Skin distribution studies of ibuprofen 
 
At the end of the ex vivo permeation experiments, the skin was removed from the cells 
(surfaces: 1.23 cm2) and rinsed with distilled water. The samples were then frozen and 
sliced horizontally with a cryostat (Figure 13, MEV Cryostat, Slee-Technik GmbH, 
Mainz, Germany). The precision of the microtome gives reproducible sections of 0 - 60 
µm in 1 µm step up to 10 µm, 2 µm step up to 20 µm and 5 µm step up to 60 µm. 
Although skin was flattened with a weight of 2 kg for 1 minute before sectioning, the 
first slices were usually incomplete because of the irregular surface of the skin samples.  
The mean thickness of the incomplete slices and skin residues was calculated from their 
weight with reference to a standard slice of known weight and thickness. 
Therefore, a mean value for the thickness per mg could be calculated : 
 
Took the mean value (mm/mg) and calculated the thickness of the incomplete cuts and 
the skin rest using their weight  (Wagner et al.,  2000).  
A sodium lauryl sulphate (SLS) aqueous solution 2% w/v (20 mg/ml) was prepared 
(SLS/Sol) and Ibu was extracted from the skin slices by treatment with 1.0 ml of  
SLS/Sol  at room temperature for 20 hours. After addition of MeOH (2 ml) the mixture 
was maintained under stirrer for 3 hr and after it was centrifugated at 13,000 rpm for 10 
min. The samples obtained was analized by  HPLC using the analytical method for Ibu 
reported in paragraph  2.12. 
For  validation of the extraction procedure, a different series of 20 or 25 µm slices of 
blank skin was submitted to the assay, and the retention time of endogenous 
compounds was compared with that of Ibu and ASCn to verify that there were no 
interferences in analyzing the drug.  
The extraction recovery was determined by computing the ratio of the amount of drug 
extracted from the skin to the amount added (Tampucci, 2005). 
 
 
 
 
 
∑
∑=
slice complete ofweight 
slice complete of thickness
 mean value
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Figure 13.  Picture of Cryostat  ( Mev Slee Technik GMBH.). 
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2.11 Analytical method for Ibuprofen 
 
The concentration of IBU in the receiving phase  and in the aqueous sample obtained 
after skin extraction process was determined by HPLC (see section 2.6.1). 
The amount of drug  in the samples was determined by comparison with appropriate  
standard curves. The external standard curve was obtained adding different  amounts of 
a Ibu standard solution  prepared in MeOH   (SM1=92,4 mg/100ml and SM2= 63,2 
mg/100 ml) (SM1=15,45,50 μl and SM2= 10, 20, 30 μl ) directly to blank skin slices, 
which were submitted to  the extraction procedure already described. 
 
Standard curves 
ASCn and IBU samples obtained from the in vitro released and ex vivo permeation 
studies. 
A stock standard solution of ASCn (SSB/ASCn)  and Ibu (SSB/Ibu) was prepared by 
solubilization in methanol of an appropriate amount of each ASCn derivatives and IBU 
exactly weighed, respectively. Then, in both cases, several dilutions (SM1= 1:50;  
1:100; 1:200 and SM2= 1:50;  1:100; 1:200) in isotonic buffer phosphate solution pH 
7.4 were prepared and injected (20 μl) into the HPLC using a manual sampler system. 
The determination coefficients (r2) of all compounds were calculated. 
 
 ASCn and IBU samples obtained from Skin distribution studies. 
A stock standard solution of ASCn (SSB/ASCn)  and Ibu (SSB/Ibu) were prepared by 
solubilization in methanol of an appropriate amount of each ASCn derivatives and Ibu 
exactly weighed, respectively. Then, several dilutions (SM1= 1:50;  1:100; 1:200 and 
SM2= 1:50;  1:100; 1:200) in MeOH were prepared and injected (20 μl) into the HPLC 
using a manual sampler system. 
The determination coefficients (r2) of all compounds were calculated. 
 
Lower limit of quantification 
The lower limit of quantification is defined as the concentration of the lowest standard 
in the analytical run which is quantified with a deviation of the actual concentration and 
a coefficient of variation of precision of less than 20%. This practice was made for each 
HPLC analysis. 
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2.12 Data Analysis 
 
The apparent corneal permeability coefficients (Papp) in units of centimeters per hour, 
as defined by the equation: 
Papp = (dQ/dt)/(AC0) 
 
where A and C0 are the exposed substrate surface area (1.23 cm2 ) and the initial Ibu 
concentration, respectively, were calculated from the steady-state slopes of linear plots 
of amount of drug in the receiving chamber (Q) versus time (t). The lag times, i.e. the 
times taken by the drug to saturate the skin and to attain steady-state permeation, were 
calculated as intercept values on the x axis using the same plots.  
The enhancement factors (EF), expressing the relative activity of each treatment, were 
calculated from the ratio Papp (CIbu)/Papp(R), where Papp(CIbu) and Papp(R) are the 
apparent permeability coefficients calculated  for the coagels and for the commercial 
referente formulation, respectively. 
Linear regression analysis (slopes and intercepts) were performed using Excel software. 
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2.13 Preparation of formulations containing diclofenac  
 
2.13.1 Preparation of the coagels 
 
Coagels were prepared by heating  (2% w/w of ASC12 and ASC16  aqueous suspensions 
above their phase transition temperature (CMT = 47.3 °C, ASC12;  63.8 °C, ASC16, 
Palma, 2003b) and adding DICH (0.1% w/w) until the gel phase was formed. The 
systems were kept to of over TMC for 2 hours in order to obtain the complete 
solubilization of the drug, and then, they were permitted to reach room temperature to 
obtain the respective ASC12 and ASC16 coagels (ASC12/CDich and ASC16 /CDich). 
Glucose mono hydrate (5% w/w) was added to obtain  isotonic formulations. 
The osmolarity  was measured  with  Osmometer Roebling and resulted of 296 ± 1 and 
298 ± 1  mOml/L for ASC12/CDich and ASC16 /CDich, respectively. 
 
2.13.2 Preparation of the aqueous suspension (Dich-D) 
 
The 0.1% w/w DICH suspension was prepared in  aqueous solution containing 5% w/w 
of glucose mono hydrate. The osmolarity  was measured  with  Osmometer Roebling 
and resulted of 295 ± 1 mOml/L. 
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2.14 In vitro release of  diclofenac from  coagels   
 
Dialysis bags (cut off = 3000-3500 Da) were filled with a fixed amount  (1g) of coagel 
formulations (ASC12/CDich and ASC16/CDich)  or reference formulations  (Voltaren 
Ophta® and Dich-D) and they was put into isotonic buffer phosphate solution pH 7.4 
(1.33 mM), chosen as receptor phase. The receptor phase was stirred and thermostated 
at 37°C. At fixed time, samples of the receptor phase were withdrawn and replaced 
with fresh fluid. The amount of  drug released in the receptor phase  was assayed by 
HPLC.  
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2.15 . Ocular in vivo studies on the rabbit eye. 
 
 
2.15.1 Intraocular penetration study  
 
Ocular pharmacokinetics was performed on rabbits  after ocular administration of on 
the coagels, Dich-D and  of the commercial formulation Voltaren Ophta® (Ciba 
Vision) as references. 
Male, New Zealand albino rabbits, ranging in weight from 2.5 to 3.0 kg (Pampaloni 
Rabbitry, Fauglia, Italy) were used and treated as prescribed in the publication Guide 
for the Care and the Use of Laboratory Animals (NIH Publication No. 92–93, revised 
1985). The in vivo experimental protocol was approved by the Ethical-Scientific 
Committee of the University of Pisa and the experiments were carried out under 
veterinary supervision. 
The animals  (three groups, each of eight rabbits) were housed singly in standard cages, 
in a light-controlled room (10 h dark/14 h light cycle) at 19±1 °C and 50±5% RH, with 
no restriction of food or water. During the experiments the rabbits were placed in 
restraining boxes: they were allowed to move their heads freely, and their eye 
movements were not restricted. 
An amount corresponding to 50 μl of the preparations ASC12/CDich and ASC16/CDich, 
Dich-D and Voltaren Ophta
®
 were administered in the lower conjunctival sac of one 
eye of each rabbit.See composition of formulations in Table 9. 
The administered    diclofenac dose was, in all cases, 0,05 mg. 
The animals' eyes were examined with a slit-lamp to evidence possible signs of 
irritation every 10 min up to 1 h after administration of the experimental formulations. 
At appropriate time intervals the rabbits were anaesthetized by intramuscular injection 
of 8.73 mg Kg–1 tiletamine hydrochloride and 8.63 mg Kg–1 zolazepam hydrochloride 
(Zoletil 100®, Laboratories Virdac, Carros, France)  and a sample of 50-60 μl of 
aqueous humour was removed from the anterior chamber using a 1.0 ml syringe (29G, 
Micro-Fine, Beckton Dickinson, Dublin, IRL). The aqueous humour samples were 
immediately frozen and stored at −18 °C. For analysis, the samples were mixed with an 
equal volume of methanol after centrifugation 15 min at 13000 rpm, Microcentrifugette 
4214, A.L.C. International Srl, Milan, Italy 20 μl of the supernatants were submitted to 
HPLC analysis. 
 51
2.15.2 In vivo precorneal residence measurements.  
 
After administration of a predetermined amount of each formulation (Table 9) (50 μl) 
in the lower conjunctival sac of one eye of each rabbit, the rabbit lachrymal fluid (1 μl) 
was withdrawn, by means of a capillary (Microcaps, Drummond Scientific, NJ, USA), 
from the conjunctival sac with the following schedule: 2, 5, 10, 20, 30 min.  The 
samples were collected in microtubes and the capillary washed with an equal volume of 
distilled water. Then the samples were immediately frozen and stored at −20 °C until 
the HPLC analysis was performed. The sample was diluted with 50 μl of MeOH 
(Burgalassi et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
2.16 Analytical method for Diclofenac 
 
The concentration of DICH  in the receiving phase, in the tear fluid and  in the aqueous 
humour samples was determined by HPLC (see section 2.6.1) 
 
 
 DICH samples obtained from in vitro release studies. 
A stock standard solution of DICH (SSb/Dich) was prepared by solubilization in 
methanol of an appropriate amount of DICH exactly weighed. Then, several dilutions 
(SM1= 1:50;  1:100; 1:200 and SM2= 1:50;  1:100; 1:200) in isotonic buffer phosphate 
solution pH 7.4 were prepared and injected (20 μl) into the HPLC using a manual 
sampler system. 
The determination coefficients (r2) of all compounds were calculated. 
 
 
DICH tear fluid samples obtained from in vivo studies. 
A stock standard solution of DICH (SSM/Dich) was prepared by solubilization in 
methanol of an appropriate amount of DICH exactly weighed. Then, several dilutions 
(SM1= 1:50;  1:100; 1:200 and SM2= 1:50;  1:100; 1:200) in MeOH were prepared and 
injected (20 μl) into the HPLC using a manual sampler system. 
The determination coefficients (r2) of all compounds were calculated. 
 
 
DICH aqueous humour samples obtained from studies in vivo studies. 
A stock standard solution of DICH (SSC/Dich) was prepared by solubilization in 
methanol of an appropriate amount of Dich exactly weighed. Then, several dilutions 
(SM1= 1:50;  1:100; 1:200 and SM2= 1:50;  1:100; 1:200) in MeOH were prepared. 50 
µl of  these dilutions mixed with 50µl of  aqueous humor were dried under reduced 
pressure (Jouans® RC 10.09; Jouans® RCT 60). After, every sample was treated with 
50µl of MeOH and centrifuged at 13000 rpm for 10 min and injected (20 μl) into the 
HPLC using a manual sampler system. 
The determination coefficients (r2) of all compounds were calculated. 
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Lower limit of quantification 
The lower limit of quantification is defined as the concentration of the lowest standard 
in the analytical run which is quantified with a deviation of the actual concentration and 
a coefficient of variation of precision of less than 20%. This practice was made for each 
HPLC analysis. 
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2.17 Pharmacokinetic and Statistical Analysis 
 
Statistical differences between means of the formulations under study concentration in 
the tear fluid and in aqueous humor were evaluated using an analysis of variance 
(ANOVA) test (GraphPad, San Diego, CA). The statistical significance of the 
differences between treatments was calculated by GraphPad Prism software (GraphPad, 
San Diego, CA) using the Student’s unpaired t-test. The evaluation included calculation 
of means and standard errors (standard error of the mean) and group comparisons using 
multiple comparisons Fisher PLSD test. Differences were considered statistically 
significant at  P<0.05.  
AUC values (areas under plots of concentration against time) for the formulations under 
study in aqueous humor were calculated from the beginning (to) to the end of the 
observation time (tlast) from appropriate graphs, and AUC0-∞ values for these 
formulations in the tear fluid were calculated  from the beginning (to) to the infinitely  
time (t∞) from appropriate graphs calculated by GraphPad Prism software (GraphPad, 
San Diego, CA).  
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3. Results  and Discussion 
 
Many drugs developed in the topical formulations for cutaneous and ocular  diseases are 
poorly water-soluble and difficult to formulate. Ideally, to maximize delivery, the 
largest possible amount of drug should be dissolved in the formulation and became 
immediately  bioavailable to the lipophilic stratum corneum of the skin or on the 
epithelial stratum of the cornea. 
In the case  of water insoluble  drugs, the incorporation  in a semisolid vehicles  capable 
of favoring the penetration of the drugs in the biologic structure, for example  as 
penetration enhancer, could be an interesting strategies to increase their 
pharmacological activity. 
It has been reported that more than 50% of the compounds developed by the 
pharmaceutical industry are poorly soluble in aqueous media and the conventional 
pharmaceutical  formulations  containing poor water soluble compounds are often 
associated with low and unpredictable bioavailability of drugs (Lipinski, 2001; 
Stegemann et al., 2007).  
The great hydrophobic characteristics of the ASCn coagels seems to be an interesting 
tool for the loading of drug with low aqueous solubility (Palma et al., 2007). ASC10 
supramolecular  structures dissolve hydrophobic drugs such as danthron, phenacetin and 
griseofulvin in their lipophilic inner cores, and significantly enhance their solubility and 
availability in the aqueous phase, with respect to the use of free drugs in  pure water 
(Palma et al., 2003a). In particular,  it was  observed that  the incorporation of anthralin, 
a very unstable drug in aqueous solution, in  all ASCn coagels,  produced  an increase in 
drug solubilization. Besides,  the anthralin solubilized in coagel showed higher stability 
with respect to  also  ethanol/aqueous solutions (Palma et al., 2007).  
After a first step concerning the characterization of ASC12 derivative performed by 
DSC,  the influence  of  a  co-solvent (PEG 400) on the capacity of the ASC16  coagels   
to load  and  to stabilize two model drugs with low water solubility, such as anthralin 
(ANTH) and griseofulvin (GRIS), was evaluated.  
The chemical-physical characterization of the ASC12 derivative, synthesized in our 
laboratory, was carried out with DSC: an endothermic peak was evidenced in the range 
45-55°C in accord with the reported data (Palma , 2003b) (Figure 14). 
For dissolution studies, it was measured the solubility of ANTH and GRIS in the 2 
%w/w ASC16  coagel,  when the amount of co-solvent (PEG 400) was increased in the 
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range  between 10 and 70 %w/w. The experiments were carried out in triplicate and the 
results were  plotted  in the  Figures 15 and 16, as amount of dissolved drugs versus 
concentration of PEG 400. In the both cases, for ANTH and for GRIS,  the solubility 
was higher with the increase of the concentration of co-solvent, and a more  rapid rise of 
the  solubility was observed when the  PEG concentration was higher than  50 and 30% 
respectively for ANTH and GRIS. 
In the Tables 18 and 19, the solubility, the molar ratio (MR) and the loading capacity 
(LC) for ANTH and GRIS in the different solutions are summarized. The  LC capacity 
corresponds to the grams of drug for each 100 grams of coagel and MR defined the 
moles of ASC16 for each mole of the drug solubilized. For both drugs, ANTH and 
GRIS, MR values decrease with the increasing of the concentration of PEG 400, and a 
lower reduction in the MR values were calculated for GRIS. In particular, when 
concentration of PEG 400 in the coagel  containing ANTH, was 10 % w/w, MR value 
was 29.3 ± 1.3 while when the concentration of the co-solvent was  70% w/w, MR 
value was   5.8 ± 0.3. A same trend was showed  in the LC  values, in fact  these values  
were higher with the increasing of the PEG in the system.  The LC value for ANTH in 
the coagel based on the 70% w/w of PEG 400 was  five times higher than that  
calculated for the coagel  containing  10 % w/w of PEG 400.  
For  GRIS this behavior is more evident: the LC value was 12 times higher in the 
system with 70 % w/w of PEG 400 with respect to the LC calculated  for the coagel 
with the 10 % w/w of the co solvent. Furthermore,  analyzing the MR values for ANTH 
and GRIS, it was evident that with the increasing of the PEG 400 in the system, is 
necessary a lower amount of ASC16 to load the same amount of the drug. 
 
In order to characterize  coagels used as  topical formulation (Table 5), their physical 
structure was investigated by performing rheological measurements. The rheograms 
obtained are reported in the Figures 18-21. As reported above (see section 1.3.1), all 
coagels showed a complex rheology, with the appearance of “spur”  points on the 
ascending curve of  the rheogram that is typical of the structure defined “house of 
cards”   where swelling and strengthening  of the semisolid network  occurs due to the 
presence of water between  the amphiphilic bilayers.  
The influence of the IBU and DICH on the crystalline structure of coagel was studied. 
In the Figures 18a, 18b, 19a and 19b the results obtained for ASC12/C(5%),  
ASC12/CIbu, ASC16/C(5%) and ASC16/CIbu, respectively are plotted. The rheological  
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profiles demonstrated that the incorporation of IBU in the system did not produce 
changes on the crystalline structure typical of the coagels, in fact the spur value is 
present in each rheogram. Besides, viscosity  profile of ASC12/CIbu and ASC16/CIbu 
demonstrated a highly structured system similar to that of ASC12/C(5%) and 
ASC16/C(5%), respectively,  indicating that IBU was solubilized into the lamellar zone  
(Palma et al., 2003a). 
In order to establish the importance of coagel structure for its function in our studies, a 
formulation with the disrupted structure was prepared (ASC16/Ibu) and its rheological 
behavior was evaluated.  ASC16/CIbu was stirred (600 rpm) at room temperature to 
obtain  the  ASC16 with its structure disrupted (ASC16/Ibu). The viscosity profile 
illustrated in Fig 19c, showed that ASC16/Ibu exhibited a pseudo plastic behavior, 
confirming the absence of the lamellae form as “house of card” in the structure of the  
ASC16/Ibu (Palma  et al., 2003a). 
The same studies were performed on ASCn formulations with DICH in order to know 
the effect of both drug and glucose on coagel structure. Figures 20a, 20b, 20c, 21a, 21b 
and 21c show the rheological behavior of ASC12/C(2%), ASC12/CGlu, ASC12/CDich, 
ASC16/C(2%), ASC16/CGlu and ASC16/CDich, respectively. As can be seen in  Figure 
20b and 21b, the presence of the glucose in coagels of ASC12 and ASC16 did not 
produce an important change on the crystalline structure of the coagels, in fact the spur 
value is always present in each viscosity profile.  
In the Fig 20c and 21c, the shear stress vs the shear rate of ASC12/CDich and 
ASC16/CDich, respectively was plotted. These rheological  profiles demonstrated that 
the simultaneous incorporation of  both  DICH and glucose in the system did not 
produce changes on the characteristic crystalline structure of coagels, as the presence of 
the spur value in the rheogram demonstrated. Furthermore, viscosity  profile of 
ASC12/CDich and ASC16/CDich showed a highly structured system similar to the 
structure of  ASC12/C(2%) and ASC16/C(2%), respectively, (Figures 16a and 17a)  
indicating that DICH was solubilized into the lamellar zone  (Palma et al., 2003a).  
                  
The in vitro release profiles of IBU from different formulations are illustrated in the 
Figures  22-24. 
The release kinetics were analyzed using the well-known semi-empirical relationship:  
                                                              
Mt/M∞ = Ktn 
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Where Mt/M∞ is the drug fraction is the drug fraction release at time t, while K and n 
constant characteristic of the matrix – eluent systems. In particular, the exponent n is 
indicative of release kinetics. Peppas (1985) used this n value in order to characterize 
different release kinetics: n=0.5, Fickian diffusion transport mechanism; n=0.5<n<1.0 
anomalous transport; n=1.0 zero order release; n>1 anomalous transport. 
 
 
   Table 15   Interpretation of diffusional release mechanisms from polymeric films. 
 
       Release exponent                   Drug transport                          Rate as a    function 
        (n)                                     mechanism                                      of the time 
                 
     0.5                                               Fickian diffusion                            t -0.5 
     0.5<n<1.0                                   Anomalous transport                      t n-1 
    1.0                                               Case-II transport                             Zero order release 
    Higher than 1.0                            Super Case-II transport                  t n-1 
 
 
 
The main in vitro release parameters are reported in the Table 10, for  all formulations 
under study (Table 8). Data represent mean of  4 replicates ± standard error (SE).  
Table 10 summarizes for each formulation tested, in addition to n an K values, t30% and 
t60% values (time required to release 30 and 60% of drug, respectively) and  R30% and 
R60% values (instantaneous release rates at 30 and 60% released drug, respectively). 
Even if some calculated interpolation curves (Fig 22, 23, 24) appeared to indicate a non-
ideal fit, the relevant correlation coefficients (r) were in the range 0.967-0998.  
Coagels, except ASC12PG400/CIbu, have the n values near 1.0, indicative of a linear 
kinetic while Arfen® and Ibu-S gave 0.70 and 0.74 values of n, respectively, 
demonstrating an anomalous drug release. Both ASC12PG400/CIbu and PEG-D showed 
an anomalous release with n values grater than 1.0 (1.51 ± 0.07 and 1.25 ± 0.01, 
respectively). By analyzing in vitro release data it is possible to note that the release of  
IBU from  Arfen followed from Ibu-S through the dialysis membrane was characterized 
by fast diffusion:  60% of drug was released in 40.15 and 51.36 min for Arfen® and Ibu-
S, respectively with a release rate of 1.30 ± 0.05 and 1.12 ± 0.03%/min, respectively. A 
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more gradual release was obtained when the coagel formulations was used: t60% was 
included between 113.02 ± 0.69 and 359.74 ± 36.74 min for ASC16/Ibu and 
ASC16PG400/CIbu, respectively. In the case of coagels,  the release rate generally rose 
by decreasing the length of alkyl chain: 0.27 ± 0.01 %.min-1  for ASC16/CIbu with 
respect to 0.49 ± 0.08 %.min-1 for ASC12/CIbu (see Figure 22). In order to know the 
influence of the coagel structure on the release profile of IBU, a formulation with its 
structure disrupted (ASC16/Ibu) was studied.  In Figure 23 the percentage of  IBU 
release from ASC16/Ibu and ASC16/CIbu is plotted versus time: the absence of second 
dimensional structure did not modify the release kinetic (n∼1 for both formulations) 
while, as highlighted in the Table 10, the release rate of ASC16/Ibu was twice higher 
than ASC16/CIbu. 
 
The in vitro permeation parameters of IBU from formulations (flux, apparent 
permeability coefficient, lag time , amount of IBU permeated after 20 h) are listed in 
table 11. Arfen®, commercial product, was used as reference. Data represent the mean ± 
standard error. Figures 25-31 illustrate permeation profiles of IBU from formulations 
under study (Table 8).   Commercial product,  Arfen®, produced the lowest values of 
steady-state flux and Papp of IBU  (J= 13.97 ± 1.47 mg/cm2h and Papp= 0.24  ± 0.023 
cm. h-1. 103). On the contrary, Ibu-S formulation containing the drug dissolved in a 
isopropanol: phosphate buffer mixture (20:80) appeared the most efficacy formulation 
on improving IBU transdermal permeation: J= 108.93 ± 12.89 mg/cm2h; Papp= 13.21 ± 
1.50 cm. h-1. 103.  It’s known (Goldberg-Cettina et al., 1995) the role of isopropanol as 
cutaneous enhancer to lipophylic drugs, moreover increasing drug solubility on the 
vehicle and consequently the thermodynamic activity.  
ASC12/CIbu and ASC16/CIbu coagels formulations increased IBU transdermal 
permeation of  21.5  and 11.9 - times compared to Arfen®, respectively, demonstrating 
the ability of coagels to improve IBU skin permeation (see Figure 25). Besides ASCn 
derivatives were not found in the receiving phase during the permeation experiments 
lasted 20 h. ASC12/CIbu coagels appeared the most suitable vehicle to transport IBU 
through the skin . As indicated from Palma et al. 2006, ASC12 has a structural similarity 
to other chemical enhancers like Azone and oleic acid.  It was suggested that Azone 
exists in a “spoon-shaped conformation” and may alter the properties of the SC lipids 
by insertion and opening-up of adjacent ceramide molecules (Williams and Barry, 
2004). As indicated from Palma et al. 2006, ASC12 may adopt this “spoon-shaped” 
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conformation and consequently be able to insert itself between ceramide molecules. 
Nevertheless the bigger polar head of ASC12 and its lower lipophilicity might allow this 
surfactant to penetrate into the SC. The use of ASC16/CIbu did not determine 
advantages compared to  ASC12/CIbu (Papp= 2.86.10-3 ± 0.31.10-3 and 5.17.10-3 ± 
1.37.10-3 cm h-1) but the breaking down of structurate form (ASC16/Ibu) produced 
further decrease of skin permeation (Papp= 1.90.10-3 ± 0.18.10-3 cm h-1) (see Figure 31). 
Adding PEG400 to ASC12/CIbu  (ASC12PEG400/CIbu coagel) allowed to increase IBU 
cutaneous permeability up to 12.71.10-3 cm h, value comparable to that obtained with 
the aqueous/isopropanol solution of IBU (13.21.10-3 cm h-1).  The presence of PEG 400 
increase the amount of water in the skin, and in this way the permeation of IBU through 
the skin confirming literature data that described PEGs as permeation enhancer of drugs 
through the skin.. Permeation data showed a synergic enhancement effect between 
ASCn and PEG400, more evident for ASC12PEG400/CIbu coagel with respect to the 
formulation containing PEG without ASCn  (see Figure 28). Papp value of PEG-D was 
similar to that calculated for ASC12/CIbu and ASC16/CIbu coagels: 3.66 .10-3 ±  0.13. 
10-3, 5.17 .10-3 ± 1.37.10-3 and 2.86 .10-3 ± 0.31.10-3  cm h-1, respectively, against 12.71 x 
10-3 ± 1.73 x 10-3 cm h-1of ASC12PEG400/CIbu. Lag times ranged between 3.71 ± 0.28 
and 0.48 ± 0.16 hours.  As reported above, ASC12PEG400/CIbu produces the same 
permeation parameters ( flux, Papp, Lag time, ect) of Ibu-S, but it is important highlight 
that the coagels have characteristics of biocompatibility (see section 1.2) more suitable 
to the cutaneous administration with respect to the Ibu-S formulation. 
Table 12 summarizes and compares relative release rates (RR) calculated from the ratio 
between release rate of the formulation and that of Arfen® obtained from in vitro release 
studies and EF (enhancement factor) for in vitro permeation experiments through a 
natural tissue. It is interesting to highlight RR are in almost all cases  <1 meaning that 
IBU release from the formulations took place more slowly than the reference. On the 
contrary, EF values are remarkably over 1.0 changing on the basis of the type of 
formulation demonstrating the existence of the interaction between the formulation and 
the skin that facilitates the passage through the skin and overcome the reduced release 
rate of the drug. ASC12PEG400/CIbu followed from ASC12/CIbu  coagels had a high EF 
value  (52.94 ± 7.21 and 21.53 ± 5.73, respectively) in spite of a low RR value (0.12 ± 
0.01 and 0.38 ± 0.06, respectively).  
The preliminary in vitro penetration data are summarized in the Table 13 as micrograms 
of drugs per milligram of skin retained in each skin layers when the skin was put in 
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contact with ASC12/CIbu, ASC16/CIbu and Ibu-S formulations for 20 hours. Arfen was 
used as reference. 
As shown in Table 13, the Ibu-S formulation produced the highest concentration of IBU 
retained in the rat skin, both in the upper and in deeper layers; the IBU concentration 
peak from Ibu-S at a depth of 50 μm (5.80 ± 1.66 μg/mg) was higher than that obtained 
by Arfen (2.10 ± 0.63 μg/mg) and remarkably higher compared to coagels formulations 
(0.71 ± 0.03 and 0.53 ± 0.11 μg/mg for ASC12/CIbu and ASC16/CIbu, respectively). 
Coagels formulations appeared to produce a low depot on the skin that remained in the 
same order of magnitude in epidermis and derma.  
Amount of IBU distributed in the skin versus depth of the skin from the formulations 
tested is illustrates in Figure 32. 
 
The release kinetics were analyzed using the above reported relationship: Mt/M∞ = Ktn 
The main in vitro release parameters are reported in the table 14, for  all formulations 
under study. Data represent mean of 4 replicates ± standard error (SE). The n values of 
Voltaren Ophta and Dich-D formulations were indicative of an anomalous transport 
ranging from 0.48-0.72.  ASC16/CDich coagel had n=1,  corresponding to zero-order 
kinetic and ASC16/CDich coagels had n>1. The corresponding release  profiles are 
shown in Figure 33. 
Table 14 summarizes for each formulation tested, in addition to n and K values, t30% and 
t60% values (time required to release 30 and 60% of drug, respectively) and  R30% and 
R60% values (instantaneous release rates at 30 and 60% released drug, respectively. The 
inspection of the release data shows that coagels and commercial products have a same 
values of release rates ranged between 0.29 ± 0.01 and 0.35 ± 0.01%/min significantly 
lower than Dich-D formulation. This behavior can be due to the characteristics of DICH 
solubility in aqueous solution: for the suspension the release is favored from the 
presence of saturated solution while DICH release from both the coagels and 
commercial product was limited by greater affinity of drug for the vehicle with respect 
to the buffer solution.  
The results of the precorneal kinetics studies of DICH administered with all vehicle 
under investigation are summarized in table 15 and exemplified in Figure. 34. The 
parameters reported in the table are area under the concentration versus time curve  (min 
µg ml-1, AUC0-∞ ), the apparent first order elimination rate constant of  the drug from 
tear fluid (Ke, min-1), the apparent half-life of DICH in tear  fluid (t1/2, min). In all cases 
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the drug concentration in tears decreased 15 min after the administration. Dich-D has a 
rapid elimination from precorneal area: t1/2= 7.56 ± 0.83 min and Ke= 9.15 ± 1.07.10-2 
min producing a higher initial concentration (C3min) in the tear fluid and decreasing 
rapidly to low levels in 30 minutes. The other formulations under study had a peak of 
concentration at 3 min but the values were lower than that Dich-D formulation and the 
Ke values ranged between 0.024 and 0.0943 min versus 0.09 min-1 for Dich-D 
suspension (Table15, Figure 34). t1/2 values longer were observed for Voltaren Ophta 
followed by ASC12/CDich (29.40 and 18.55 min, respectively) while half-life time was 
remarkably reduced in the case of ASC16/CDich (9.43 min). At 30 min the 
concentration of ASC12/CDich in tear fluid was about 11.54 ± 1.01 μg/ml, value higher 
than that obtained with the other formulations (Figure 35). ASC12/CDich coagel 
produced a DICH  elimination from precorneal area inferior compared to that of 
ASC16/CDich formulation: this can depend on slower release of drug from 
ASC12/CDich coagel as demonstrated by t30%= 104.48 vs 81.56 min for ASC12/CDich 
and ASC16/CDich, respectively, that avoids to underground the drug to the fast 
elimination from the precorneal area. 
Some data (Cmax and AUC0-90) on transcorneal delivery of DICH from ASC12/CDich, 
ASC16/CDich, Voltaren Ophta and Dich-D are shown in Table 16 and in Figure36. 
Except to Dich-D,  the formulations under study gave a transcorneal permeation 
considerable already at 30 min. In all cases maximum of concentration was at 60 min 
but while the concentration of DICH decreased rapidly at 90 min after instillation of 
Voltaren Ophta and Dich-D, it remained higher in the case of ASC12/CDich with 
significant statistically differences with respect to the commercial formulation. 
ASC12/CDich had similar AUC0-90 value of commercial product ( 21.7 ± 2.32 and 23.44 
± 2.80, respectively) but at 90 minutes the drug amount in the aqueous humor after 
instillation of coagel was  three times higher than  that  obtained from Voltaren Ophta.  
 
The results  concerning the attempt to stabilize  the ASC16 derivative in the coagels 
using  Vitamin E as antioxidant agent are summarized in Table 20 and in Figure 33. 
In Table 20 the amount of ASC16 assessed in the formulations maintained in dark at 
different temperatures (room temperature, RT,  and 60°C) for at different time was 
reported as mean value  calculated on two samples.  
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A rapid decrease of the quantity of ASC16 derivative  was observed  in  all coagels when 
they were stored at 60°C,  even if  the samples containing Vitamin E and maintained at 
60°C  showed about 50% of derivative 8 days  after  preparation. 
At room temperature ASC16  derivative is more stable than at high temperature, in fact 
the amount of palmitoyl derivate was 96.54 ± 2.87 % and 85.35 ± 0.80 % after 3  and 30 
days of  storage  at RT respectively. On the other hand, the obtained results showed that 
the  presence of the Vitamin E was not useful to improve the stability of the ASC16 
derivative.  The formulations with Vitamin E showed about the same amount (about 
80%) of ASC16 in the un-stabilized formulation after 30 days of storage at room 
temperature. 
In conclusion, Vitamin E did not protect the derivative  by oxidation and further  studies  
are  necessary  to test other antioxidant agents or mixtures of antioxidant agents  having 
hydrophilic and lipophilic properties. 
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Table 4. Composition of formulation used for DSC analysis 
 
 
                       FORMULATION                                      COMPOSITION (% w/w) 
                                                                                
                                                                                    ASC12                       Water 
 
•   ASC12/C                                                    10.00                              90.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.  Composition of formulations used for the rheology measurements 
 
 
          FORMULATIONS                                   COMPOSITION (% w/w)                                                     
  
                                                                Ibu      Dich     ASC12     ASC16     Water     Glu        
 
•  ASC12/C(2%)                                                                   2.00                              98.00 
• ASC12/C(5%)                                                                    5.00                              95.00 
• ASC16/C(2%)                                                                                     2.00             98.00 
• ASC16/C(5%)                                                                                     5.00             95.00 
• ASC12/CIbu                                      0.85                         5.00                               94.15 
• ASC16/CIbu*                                    0.85                                          5.00              94.15 
• ASC12/CDich                                                 0.10             2.00                              92.90      5.00 
• ASC16/CDich                                                 0.10                              2.00             92.90      5.00 
• ASC12/CGlu                                                                       2.00                              93.00      5.00 
• ASC16/CGlu                                                                                        2.00             93.00      5.00  
                  *ASC16/Ibu is the coagel with its structure disrupted.      
  
 
 
Table 6.  Composition of formulations used for ASC16 stability study 
 
 
 
                             FORMULATIONS                                  COMPOSITION (% w/w)    
 
                                                                                                 ASC16      Water      Vit E   
 
•  ASC16/C(2%)                                                       2.00            98.00                            
•  ASC16/C(2%)Vit E                                              2.00            90.00           8.00 
 
 
 
 
 
 
 
 
 
 
 
  
Table 8.   Composition of formulations containing IBU 
 
 
            FORMULATIONS                                                    COMPOSITION (% w/w)                                                     
 
                                                                IBU      ASC12      ASC16      ISA         Water      PEG 400        
 
• ASC12/CIbu                                0.85        5.00                                                  94.15 
• ASC16/CIbu                                0.85                          5.00                                94.15 
• ASC16/Ibu*                                 0.85                          5.00                                94.15 
• ASC12 PEG400/CIbu                 0.85       5.00                                                   64.15           30.00 
• ASC16 PEG400/CIbu                 0.85                         5.00                                 64.15           30.00 
• Ibu-S                                            0.85                                          19.83            79.32 
• PEG-D                                         0.85                                                                69.15            30.00                                  
      
         *ASC16/Ibu is the formulation of coagel with their structure disrupted. 
          Commercial formulation:  ARFEN® 
 
 
 
 
 
 
 
 
Table 9.   Composition of formulations containing DICH 
 
   
 
             FORMULATIONS                                  COMPOSITION (% w/w)                                                     
   
                                                                  DICH    ASC12    ASC16    Water    Glu        
  
• ASC12/CDich                                             0.10        2.00                            92.90        5.00 
• ASC16/CDich                                             0.10                           2.00         92.90        5.00 
• Dich-D                                                       0.10                                           94.90        5.00           
 
     Commercial formulation: VOLTAREN OPHTA® 
 
 
 
 
 
 
 
 
 
 
 
Table 10.    In vitro release data of formulations containing IBU 
 
 
t30% and t60%, times required to release of 30 and 60% of IBU, respectively.  
R30% and R60%, instantaneous release rates at 30 and 60% released drug, respectively. 
 
 
 
 
 
Formulations Release rate (%.min-1±S.E.) 
n 
(±S.E.) 
K 
(min–n±S.E.) 
t30% 
(min±S.E.) 
R30% 
(min-1±S.E.) 
t60% 
(min±S.E. ) 
R60% 
(min-1±S.E.) 
ASC12/CIbu 0.49 ± 0.08 1.18 ± 0.01 0.22 ± 0.04 67.11  ± 10.47 0.54 ± 0.08 120.87 ± 18.84 0.60 ± 0.09 
ASC16/CIbu 0.27 ± 0.01 1.19 ± 0.09 0.11 ± 0.04 117.19 ±  6.62 0.31 ± 0.04 210.86 ± 21.09 0.35 ± 0.06 
ASC16/CB 0.57± 0.13 1.00 ± 0.01 0.56 ± 0.13 56.54  ± 15.04 0.54 ± 0.13 113.02 ± 0.69 0.54 ± 0.13 
ASC12PEG400/Cibu 0.15 ± 0.01 1.51 ± 0.07 0.02 ± 0.01 153.38 ± 12.13 0.30 ± 0.04 243.89 ± 24.39 0.38 ± 0.06 
ASC16PEG400/Cibu 0.16 ± 0.01 1.09 ± 0.05 0.10 ± 0.02 189.24 ± 13.93 0.17 ± 0.02 359.74 ± 36.74 0.18 ± 0.03 
PEG-D 0.29 ± 0.02 1.25 ± 0.01 0.08 ± 0.02 122.86 ± 9.16 0.31 ± 0.04 214.73 ± 21.31 0.35 ± 0.05 
Arfen ® 1.30 ± 0.05 0.70 ± 0.01 4.53 ± 0.41 14.96 ± 1.36 1.42 ± 0.11 40.15 ± 3.08 1.05 ± 0.07 
Ibu-S 1.12 ± 0.03 0.74 ± 0.01 3.32 ± 0.02 19.99  ±  0.43 1.10 ± 0.03 51.36 ± 1.35 0.86 ± 0.03 
 
 
 
Table 11.   Permeation parameters for IBU through hairless rat skin obtained with the different formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation J (mg.cm-2h-1.103±S.E.)
Papp 
(cm.h-1.103±S.E.) 
Lag Time 
(h ± S.E.) 
Amount of Ibu 
permeated after 20 hours 
(mg.cm-2 ± S.E.) 
ASC12/CIbu 43.27 ± 11.42 5.17 ± 1.37 0.82 ± 0.20 0.83 ± 0.21 
ASC16/CIbu 24.10 ± 2.33 2.86 ± 0.31 0.48 ± 0.16 0.47 ± 0.05 
ASC16/CB 16.17 ± 1.56 1.90 ± 0.18 0.90 ± 0.43 0.31 ± 0.03 
ASC12PEG400/CIbu 103.2 ± 13.22 12.71 ± 1.73 1.49 ± 0.04 1.94 ± 0.23 
ASC16PEG400/CIbu 41.13 ± 3.60 4.59 ± 0.36 0.53 ± 0.26 0.80 ± 0.08 
PEG-D 32.07 ± 1.56 3.66 ± 0.13 0.87 ± 0.41 0.61 ± 0.04 
Arfen ® 13.97 ± 1.47 0.24 ± 0.03 3.71 ± 0.28 0.23 ± 0.03 
Ibu-S 108.93 ± 12.83 13.21 ± 1.50 0.79 ± 0.07 2.10 ± 0.25 
 
 
Table 12.   Comparison between permeation parameters (enhancement factor) and in vitro release 
parameters (relative rate) of IBU obtained with the different formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation EF (± S.E. ) 
RR 
(± S.E.) 
ASC12/CIbu 21.53 ± 5.73 0.38 ± 0.06 
ASC16/CIbu 11.92 ± 1.28 0.21 ± 0.01 
ASC16/CB 7.91 ± 0.77 0.44 ± 0.10 
ASC12PEG400/CIbu 52.94 ± 7.21 0.12 ± 0.01 
ASC16PEG400/CIbu 19.12 ± 1.51 0.13 ± 0.01 
PEG-D 15.26 ± 0.53 0.22 ± 0.02 
Arfen ® 1 1 
Ibu-S 55.04 ± 6.27 0.86 ± 0.02 
 
 
 
 
Table 13.  Comparison of the recovery of IBU in the skin depth following topical application of the 
               formulation (ASC12/CIbu, ASC16/CIbu, Arfen® and Ibu-S) to hairless rat skin in vitro 
(mean µg/mg ± SE, n = 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Skin depth (µm) Ibu-S Arfen ® ASC12/CIbu ASC16/CIbu 
50 5.80 ± 1.66 2.10 ± 0.63 0.71 ± 0.03 0.53 ± 0.11 
100 3.11 ± 0.48 2.56 ± 0.85 0.32 ± 0.05 0.26 ± 0.04 
150 2.61 ± 0.50 0.77 ± 0.20 0.23 ± 0.01 0.34 ± 0.10 
300 2.35 ± 0.78 0.16 ± 0.04 0.32 ± 0.05 0.30 ± 0.02 
600 1.14 ± 0.31 0.42 ± 0.21 0.30 ± 0.03 0.40 ± 0.07 
 
 
 
 
Table 14.   Release profile of DICH through cellulose membrane. 
 
 
 
 
 
t30% and t60%, times required for released of 30 and 60% DICH, respectively. 
R30% and R60%, instantaneous release rates at 30 and 60% released drug, respectively.  
 
 
 
 
 
 
Formulations Release rates (%.min-1±S.E.) 
n 
(±S.E.) 
K 
(min–n±S.E.) 
t30% 
(min±S.E.) 
R30% 
(min-1±S.E.)
t60% 
(min±S.E.) 
R60% 
(min-1±S.E.) 
ASC12/CDich 0.31 ± 0.01 1.32 ± 0.03 0.07 ± 0.01 104.48 ± 2.68 0.38 ± 0.01 176.73 ± 2.93 0.45 ± 0.01 
ASC16/CDich 0.35 ± 0.01 1.06 ± 0.09 0.32 ± 0.20 81.56 ±  5.06 0.39 ± 0.01 158.16 ± 0.14 0.40 ± 0.04 
Voltaren Ophta® 0.29 ± 0.01 0.72 ± 0.08 1.53 ± 0.58 69.06  ±  6.41 0.22 ± 0.09 182.36 ± 2.35 0.24 ± 0.03 
Dich-D 1.26 ± 0.06 0.48 ± 0.03 9.36 ± 1.27 11.42  ±  1.82 1.29 ± 0.14 47.70 ± 4.18 0.61± 0.02 
  
Table 16.   Pharmacokinetic parameters in the tear fluid after topical administration of the vehicles 
containing diclofenac 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulations AUC(0-∞) (min µg ml-1± S.E.) 
Ke 
(min-1 . 10 2± S.E. ) 
t ½ 
(min ± S.E.) 
ASC12/CDich 616 ± 19 4.17 ± 0.74 18.55 ± 4.12 
ASC16/CDich 558 ± 72 9.43 ± 2.68 9.43 ± 2.66 
Voltaren Ophta ® 467 ± 105 2.42 ± 0.26 29.40 ± 3.35 
Dich-D 2807 ± 446 9.15 ± 1.07 7.56 ± 0.83 
 
 
 
 
 
Table 17.   Pharmacokinetic parameters in aqueous humor after topical administration of the vehicles 
containing diclofenac 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Formulations AUC(0-90) (min µg ml-1± S.E.) 
Cmax 
(µg. ml-1 ± S.E.) 
ASC12/CDich 21.70 ± 2.32 0.46 ± 0.08 
ASC16/CDich 12.73 ± 1.80 0.21 ± 0.03 
Voltaren Ophta ® 23.44 ± 2.80 0.53 ± 0.08 
Dich-D 17.50 ± 2.22 0.53 ± 0.06 
 
 
 
Table 18.  Solubility parameters for ANTH in  ASC16 coagel 
 
 
 
 
 
 
 
 
 
 
 
 
                                 1 moles of ASC16 for  mole of ANTH loading. 
                                 2 grams of ANTH for  100 grams of coagel. 
 
 
 
 
  
 
 
 
 
 
Concentration of 
PEG 400 
(% w/w) 
Solubility 
(g/l ± S.E.) 
MR1 
( ±  S.E.) 
LC2. 103 
( ± S.E.) 
0 0.36  ± 0.02 30.4 ± 1.9 36.0 ± 2.2 
10 0.37  ± 0.02 29.3 ± 1.3 37.0 ± 1.7 
30 0.40  ± 0.02 27.7 ± 1.6 39.0 ± 2.2 
50 0.70  ± 0.01 15.7 ±  0.1 70.0 ±  0.3 
70 1.88  ± 0.08 5.8 ± 0.3 190.0 ± 8.3 
 
 
 
 
 
 
Table 19  Solubility parameters for GRIS in  ASC16 coagel 
 
 
 
 
 
 
 
 
 
 
 
                          1 moles of ASC16 for mole of GRIS loading. 
                                      2 grams of GRIS for 100 grams of coagel. 
 
 
 
 
 
  
 
Concentration of 
PEG 400 
(% w/w) 
Solubility 
(g/l ± S.E.) 
MR1 
( ±  S.E.) 
LC2. 103 
( ± S.E.) 
0 0.56 ± 0.01 30.2 ± 0.5 56.0 ± 0.9 
10 0.75 ± 0.01 22.7 ± 0.1 75.0 ± 0.3 
30 1.29 ± 0.04 13.2 ± 0.5 130.0 ± 4.5 
50 4.08 ± 0.01 4.2 ± 0.1 410.0 ± 1,4 
70 9.35 ± 0.12 1.82 ± 0.1 930.0 ± 11.9 
 
 
 
 
Table 20.  Quantitative analysis of ASC16 derivative in the formulations  
(mean ± S.E., n=2) 
 
 
 
 
 
 
 
 
Time 
(days) 
ASC16/C(2%) 
( RT) 
ASC16/C(2%)Vit E 
(RT) 
ASC16/C(2%) 
( 60°C) 
ASC16/C(2%)Vit E 
(60°C) 
0 99.03 ± 1,48 96.63 ± 3.18 98.71 ± 1.79 99.59 ± 1.72 
3 96.54 ± 2.87 96.56 ± 2.34 64.45 ± 3.89 45.79 ± 2.87 
8 97.19 ± 2.08 91.90 ± 4.22 10.30 ± 2.68 46.79 ± 3.25 
15 82.75 ± 2.25 81.56 ± 3.22 ---- ---- 
30 85.35 ± 0.8 80.04 ± 0.95 ---- ---- 
Figure 14 DSC of ASC12/C.
Figure 15 Solubility profiles of ANTH in the ASC16 coagel in presence of PEG 400
(mean ± S.E., n=3).  
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Figure 16 Solubility profiles of GRIS in the ASC16 coagel in presence of PEG 400             
(mean ± S.E., n=3).
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Figure 18 Rheograms for (a) ASC12/C(5%) and (b) ASC12/CIbu.
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Figure 19 Rheograms for (a) ASC16/C(5%), (b) ASC16/CIbu and  ASC16/Ibu.
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Figure 20 Rheograms for (a) ASC12/C(2%), (b) ASC12/CGlu and  ASC12/CDich.
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Figure 21 Rheograms for (a) ASC16/C(2%), (b) ASC16/CGlu and  ASC16/CDich.
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Figure 22 In vitro release profile of IBU
(mean ± S.E., n=4).
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Figure 23 In vitro profile release of IBU. Comparison between ASC16/CIbu and ASC16/Ibu 
(mean± S.E., n=4).  
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Figure 24 In vitro release profile. Comparison between formulations containing PEG 400 and 
Arfen ® (mean± S.E., n=4).   
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Figure 25 In vitro IBU permeation profiles through hairless rat skin from formulations of 
coagels and Arfen ® (mean± S.E., n=4).     
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Figure 26 In vitro IBU permeation profiles through hairless rat skin of Ibu-S and Arfen ®
(mean± S.E., n=4).  
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Figure 27 In vitro IBU permeation profiles through hairless rat skin of formulations containing 
PEG 400 (mean± S.E., n=4).    
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Figure 28 In vitro IBU permeation profiles through hairless rat skin of ASC12/CIbu, 
ASC12PEG400/CIbu and PEG-D (mean± S.E., n=4).     
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Figure 29 In vitro IBU permeation profiles through hairless rat skin. Comparison betwen 
coagels containing PEG 400 and Ibu-S (mean± S.E., n=4).        
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Figure 30 In vitro IBU permeation profiles through hairless rat skin. Comparison betwen 
coagels containing PEG 400 and Arfen ® (mean± S.E., n=4).        
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Figure 31 In vitro IBU permeation profiles through hairless rat skin. Comparison between 
ASC16/CIbu and ASC16/Ibu.(mean± S.E., n=4).    
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Figure 32 Distribution of IBU through rat skin following administration of ASC12/CIbu, 
ASC16/CIbu, Ibu-S and Arfen ® (mean± S.E., n=4).      
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Figure 33  In vitro profile release of the formulations containing DICH 
(mean± S.E., n=4).  
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Figure 34  DICH concentration profiles in the tear fluid of rabbits after administration of 
formulations under study (mean± S.E., n=4).     
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Figure 35  DICH concentration profiles in the tear fluid of rabbits after administration of 
formulations under study (mean± S.E., n=4).
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Figure 36  DICH concentration profiles in aqueous humour of rabbits after administration of 
formulations under study (mean± S.E., n=4).     
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Figure 37 Stability of the ASC16 derivative
(mean± S.E., n=2).  
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